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ABSTRACT 
 
Cyclic 3',5'-guanosine monophosphate (cGMP) is a key signaling molecule 
involved in a myriad of physiological processes, including vascular smooth muscle 
(VSM) tone, water- and electrolyte homeostasis, platelet aggregation, airway smooth 
muscle tone, smooth muscle proliferation and bone formation. Increased occurrence of 
vascular disorders including erectile dysfunction, hypertension, stroke and coronary 
artery disease, have made it increasingly important to study the dynamic interplay 
between cGMP synthesis and hydrolysis in VSM cells. This dissertation examines the 
spatial distribution of intracellular cGMP, [cGMP]i, in response to NO and atrial 
natriuretic peptide (ANP) in VSM cells. To investigate the spatial patterning of [cGMP]i, 
we have developed a new generation of non-FRET (fluorescence resonance energy 
transfer) cGMP biosensors that are suitable to monitor [cGMP]i in response to 
physiological (low-nanomolar) NO and ANP concentrations and that qualify for real-
time, confocal imaging techniques. We have termed these indicators FlincGs, for green 
fluorescent indicators of cGMP.  For the development of FlincGs, we made use of the 
specific cGMP binding characteristics of PKG. We utilized site-specific mutagenesis, 
kinetic cGMP binding, dissociation and kinase assays, as well as crystallography, in order 
to investigate PKG activation and cGMP binding dynamics in greater detail. Based on 
these studies, our novel, non-FRET cGMP biosensors were designed by attaching cGMP 
binding fragments of PKG to the N-terminus of circular permutated green fluorescent 
protein. We applied FlincGs in cultured VSM cells as well as in intact tissue to determine 
whether two spatially distinct populations of guanlylyl cyclase (cytosolic versus 
membrane bound) underlie the generation of spatiotemporally-specific patterns of 
[cGMP]i formation.  
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CHAPTER ONE: LITERATURE REVIEW 
Introduction 
Cyclic 3’,5’-guanosine monophosphate (cGMP) regulates vital physiological 
processes through activation of cGMP-dependent protein kinases (PKGs), cyclic 
nucleotide gated ion channels and cGMP-specific phoshpodiesterases (PDEs) (Conti and 
Beavo, 2007; Francis et al., 2005; Hofmann, 2005; Hofmann et al., 2005), (Figure 1). 
cGMP synthesis is mediated either through soluble guanylyl cyclases (sGC) in response 
to nitric oxide (NO), or through particulate, membrane bound guanylyl cyclases (GC-
A/B) in response to natriuretic peptides (ANP, BNP, CNP) (Kuhn, 2005). Intracellular 
cGMP concentration, [cGMP]i, is kept in a dynamic balance through guanlylyl cyclases, 
that convert guanosine tri-phosphate (GTP) into cGMP and through cGMP-specific 
phosphodiesterases, that promote cGMP hydrolysis (Figure 2). cGMP binding to PKGs 
promotes phosphorylation of many downstream targets, thereby modulating a multitude 
of physiological processes. 
 
(Atrial) Natriuretic Peptide production and release 
Natriuretic peptides - atrial natriuretic peptide (ANP), B- and C-type natriuretic 
peptites (BNP, CNP) - are derived from arachidonic acid and share a common core 
structure consisting of a 17-member disulfide ring with a highly conserved internal 
sequence of (-FGXXXDRIGXXSGL-) (Kangawa and Matsuo, 1984; Sudoh et al., 1988; 
Sudoh et al., 1990). ANP and BNP are predominantly expressed in cardiac myocytes and 
act as antihypertensive and antihypervolemic factors through their actions on GC-A 
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expressed in peripheral tissues (such as VSM cells) and in the central nervous system. In 
contrast, CNP is mostly produced by vascular endothelial cells and has local effects on 
vascular regeneration (Komatsu et al., 1996; Tamura et al., 2004; Yamahara et al., 2003) 
and bone growth (Chusho et al., 2001) by binding to the specific membrane-bound 
guanylyl cyclase (GC) receptor GC-B (Garbers and Lowe, 1994). Most of our knowledge 
about the ANP/GC-A system in maintaining arterial blood pressure and blood volume has 
come from different genetic mouse models. Deletion of ANP or its receptor GC-A lead to 
arterial hypertension and cardiac hypertrophy (John et al., 1996; Kuhn et al., 2002; Lopez 
et al., 1995), whereas overexpression of ANP or GC-A lead to a decrease in arterial blood 
pressure (Oliver et al., 1998; Steinhelper et al., 1990). 
Main triggers for the release of ANP from atrial secretory granules in cardiac 
myocytes are an increase in wall stretch, pressure and ischemia (de Bold et al., 1981; de 
Bold et al., 2001), but neurohumoral factors (glucocorticoids, catecholamines, arginine 
vasopressin, angiotensin II and endothelin) may also play a role (Ruskoaho, 1992) 
(Figure 3). Once in the bloodstream, ANP activates the GC-A receptor in peripheral 
tissues to increase [cGMP]i (Garbers and Lowe, 1994) (Figure 1) and thereby modulates 
blood pressure and blood volume in an endocrine fashion through vasorelaxation, diuresis 
and natriuresis.  
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Nitric Oxide synthesis and release 
Besides natriuretic peptides, increasing concentrations of [cGMP]i are also 
mediated through the action of nitric oxide (NO) on soluble guanylyl cyclases (sGC) 
(Figure 1). In vascular endothelial cells, NO is produced by the endothelial nitric oxide 
synthase, eNOS (Palmer et al., 1988). Activation of eNOS occurs primarily through 
agonist-modulated increases in intracellular calcium, and binding of Ca2+-calmodulin to 
eNOS (Figure 4).  Endogenous ligands for G-protein coupled receptors that mobilize 
calcium and activate eNOS include acetylcholine (which signals via M3 muscarinic 
receptors), histamine, adenosine, ATP/ADP, thrombin, and bradykinin (Moncada et al., 
1991). Stimulation of NO-synthesis can also be initiated through shear stress (via 
mechanoreceptors) (Gudi et al., 1998), or through phosphorylation and de-nitrosylation 
of eNOS (via sphingosine 1-phosphate, VEGF or insulin) (Dimmeler et al., 1999; Erwin 
et al., 2005; Kou et al., 2002; Montagnani et al., 2001; Olivera and Spiegel, 1993). 
Catalytically active eNOS converts L-Arginine to NO and L-Citrulline. NO is then 
released and can freely diffuse into cells. NO has a short half-life of approximately 5 sec 
and is buffered in the blood stream through binding to the ferrous heme moiety of 
hemoglobin.  The physiological effects of NO in the vasculature are mediated through 
increased [cGMP]i via sGC and include inhibition of leukocyte adhesion and platelet 
aggregation, suppression of smooth muscle cell proliferation and induction of vascular 
smooth muscle relaxation, leading to vasodilation (Hofmann, 2005).  
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Guanylyl cyclase mediated synthesis of [cGMP]i
Guanine nucleotidyl (guanylyl) cyclases (GCs) are widely distributed signal-
transduction enzymes that, in response to NO and natriuretic peptides, convert GTP into 
the second messenger cyclic GMP (Figure 2). The diffusible gas NO targets the heme 
containing enzyme soluble guanylyl cyclase (sGC), a protein ubiquitously expressed in 
mammalian cells. Studies from sGC-deficient mice have shown that NO-sGC signaling is 
essential for the maintenance of normal peristalsis in the gut, and for the regulation of 
blood pressure and vascular smooth muscle tone (Friebe et al., 2007; Mergia et al., 2006; 
Nimmegeers et al., 2007). sGC is a heterodimeric protein, consisting of a larger alpha-
subunit and a smaller heme-binding beta-subunit (Figure 5). Four human sGC subunits 
exist: α1, α2, β1 and β2, of which the α1/β1 and α2/β1 heterodimers are best characterized 
(Mayer and Koesling, 2001; Zabel et al., 1998). The β-subunit contains a conserved 
amino-terminal heme-binding domain (Iyer et al., 2003; Pellicena et al., 2004), which is 
crucial for NO sensing. NO-induced activation of sGC depends on the presence of the 
reduced Fe2+ heme moiety (Ignarro et al., 1986). Binding of NO (10 to 100 nM; (Mo et 
al., 2004)) to the central ferrous iron of the prosthetic group induces conformational 
changes in the C-terminal catalytic domain, leading to a 400-fold increase in activity of 
sGC (Mayer and Koesling, 2001) and to conversion of GTP into cGMP and 
pyrophosphate (Figure 2). The catalytic domains of both subunits are required for the 
formation of a catalytically active center (Winger and Marletta, 2005). In recent years, 
Marletta and colleagues have reported a second NO binding site (Ballou et al., 2002; 
Cary et al., 2006; Zhao et al., 1999), suggesting a more complex mechanism of sGC 
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activation. sGC activity can be increased through commercially available compounds that 
act either as heme-dependent sGC stimulators (YC-1, BAY 41-2272, BAY 41-8543, 
CFM-1571 and A-350619) or as heme-independent sGC activators (BAY 58-2667 and 
HMR-1766) (Evgenov et al., 2006; Schindler et al., 2006). Oxidation of sGC inhibits 
cyclase activity, and is typically generated through the use of the pharmacological agents 
ODQ (1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one), NS2028, methylene blue or 
ferricyanide (Hwang et al., 1998; Olesen et al., 1998; Schrammel et al., 1996; Zhao et al., 
2000). Endogenously, changes in the redox state of sGC can be induced by reactive 
oxygen and nitrogen species such as superoxide (O2-) and peroxynitrite (ONOO-), which 
are generated under conditions of oxidative stress (Stasch et al., 2006). Carbon monoxide 
can bind to the sGC heme group, but increases sGC activity only by a factor of 4, 
underscoring the requirement for the particular NO-mediated conformational change (Ma 
et al., 2007). 
In contrast to sGCs, the transmembrane particulate GCs (GC-A and GC-B) serve 
as a receptor for atrial, B-type (GC-A) and C-type (GC-B) natriuretic peptides. GC-A/B 
possess a variable N-terminal extracellular receptor domain, a transmembrane domain 
and an intracellular region consisting of a protein kinase–homology domain (KHD), an 
amphipathic alpha-helical or hinge region, and a C-terminal cyclase–homology catalytic 
domain (Chinkers and Garbers, 1989; Liu et al., 1997; Wilson and Chinkers, 1995) 
(Figure 5). Transmembrane particulate GCs exist as homodimers, and dimerization is 
required for full catalytic activity. Binding of natriuretic peptide to the extracellular 
receptor domain induces conformational changes that lead to cGMP synthesis in the 
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intracellular catalytic domain (Figure 2). The KHD domain modulates the enzyme 
activity of the C-terminal catalytic domain (Koller et al., 1992). Although the KHD 
domain binds ATP and contains many residues conserved in the catalytic domain of 
protein kinases, this domain possesses no intrinsic kinase activity. Catalytic activity of 
membrane GC can also be modulated through purine nucleoside analogs (P-site 
inhibitors) (Joubert et al., 2007).  
Both families of guanylyl cyclases, sGC and GC-A, catalyze the synthesis of 
[cGMP]i upon stimulation. Due to their distinct cellular localization - membrane bound 
GC-A versus cytosolic sGC - in combination with the hydrolyzing properties of PDEs, 
both families of GCs may give rise to distinct pools of [cGMP]i and may differentially 
modulate the activity of specific target proteins such as phosphodiesterases, ion channels, 
cGMP-dependent protein kinases, and downstream cellular events. 
 
Phosphodiesterase mediated hydrolysis of cGMP 
In VSM cells and platelets, the GC-mediated increase in [cGMP]i is held in a 
dynamic balance through the hydrolyzing activity of cGMP-specific phosphodiesterases 
(PDEs) (Figure 2) (Cawley et al., 2007; Mullershausen et al., 2001). Based on substrate 
affinity, selectivity, and regulation mechanisms, PDEs have been grouped into 11 
different isoenzymes (Conti and Beavo, 2007; Kass et al., 2007). Of these enzymes, 
PDE5, PDE6, and PDE9 are highly selective for cGMP, PDE1, PDE2, and PDE11 have 
dual substrate affinity, and PDE3 and PDE10 are cGMP-sensitive but cAMP-selective. In 
VSM cells, the primary cGMP-PDEs with known activity are PDE1 and PDE5. PDE1 is 
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a calcium/calmodulin-dependent enzyme while PDE5 is the first identified selective 
cGMP esterase. PDE3, a cAMP esterase expressed in VSM cells, can be inhibited by 
cGMP. 
In addition to being hydrolyzed by PDEs, cGMP can modulate the catabolic 
activity of these enzymes by binding to tandem regulatory GAF domains, which are 
named for the first three classes of proteins found to contain the cGMP-binding sequence: 
mammalian cGMP-binding PDEs, Anabaena adenylate cyclase, and Escherichia coli 
Fh1A. In the case of PDE5, binding of cGMP to the two GAF sites induces a 
conformational change in PDE to activate its catabolic activity and to stimulate cGMP 
hydrolysis (Okada and Asakawa, 2002; Rybalkin et al., 2003). PDE1 does not contain 
any GAF sites. Another mechanism to modulate PDE activity involves phosphorylation 
by PKG. For PDE5, GAF binding promotes phosphorylation through PKG (at 10 x 
greater rates than through PKA) (Thomas et al., 1990; Turko et al., 1998). PKG 
phosphorylation in turn induces a conformational change that increases the cGMP-
binding affinity in the regulatory GAF domain, and enhances cGMP catalytic activity by 
50–70% (Corbin et al., 2000).  PDE5 may also serve as an intracellular storage site by 
allosterically binding cGMP, thus protecting cGMP from hydrolysis and potentially 
releasing it when cGMP levels decline due to other signaling events (Gopal et al., 2001). 
A third type of functional modulation occurs via cGMP at the catalytic site. PDE3 binds 
both cAMP and cGMP at its catalytic site at high affinity. However, cGMP can function 
as a competitive inhibitor of PDE3-mediated cAMP hydrolysis (Leroy et al., 1996), and 
at low levels of cGMP, the effect is to enhance cAMP and its downstream effects. 
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PDE5 has been shown to play a key role in smooth muscle tone, for example in 
the corpus cavernosum and the pulmonary vasculature. Protein expression and activity 
are also well documented in the cerebellum, stomach, small and large intestine, bladder, 
and platelets (Lin et al., 2006). The recent development of highly specific inhibitors such 
as sildenafil, tadalafil and vardenafil for PDE5 and vinpocetine for PDE1 has greatly 
enhanced our understanding of PDEs. Recent studies in platelets and in aortic tissue have 
shown that NO triggers an initial rise and then rapid decline in [cGMP]i (Cawley et al., 
2007; Mullershausen et al., 2001). These studies suggest that auto-activation of PDE5 by 
cGMP plays an important feedback role in NO signaling.  
 
cGMP dependent protein kinases (PKGs) 
PKG belongs to the family of Ser/Thr protein kinases and transmits changes in 
[cGMP]i into downstream signaling events in all eukaryotes (Figure 1). Mammals 
uniformly express two PKG genes, prkg1 and prkg2, that encode PKG type I and type II 
(Francis and Corbin, 1999; Pfeifer et al., 1999). Two alternatively spliced exons give rise 
to the isoforms PKG I α and β that differ only in their N-terminal 90 to 100 residues and 
the cGMP concentration required for kinase activation (Ruth et al., 1991). 
 
PKG-Structure and Function 
Structurally, the PKG holoenzyme exists as parallel dimer of two identical 
subunits, with each subunit possessing an N-terminal dimerization and autoinhibitory 
domain, followed by a cGMP binding regulatory domain and a catalytic domain (Figure 
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6) (Francis and Corbin, 1999; Pfeifer et al., 1999). PKG homodimers are held together by 
a parallel, alpha-helical leucine zipper present in the N terminus (Schnell et al., 2005), 
and are targeted to different subcellular localizations by their N-termini via G-kinase 
anchoring proteins (GKAPs) (Cha et al., 2005), acetylation or myristoylation 
(MacMillan-Crow and Lincoln, 1994; Vaandrager et al., 1997). The regulatory domain 
contains two in-tandem cGMP receptor sites, A and B that interact allosterically and bind 
cGMP with different affinities. Occupation of both binding sites induces a large change 
in secondary structure (Landgraf et al., 1990) to yield a more elongated molecule (Richie-
Jannetta et al., 2006; Wall et al., 2003; Zhao et al., 1997). The catalytic domain includes 
the Mg2+-ATP- and substrate recognition sites. Binding of cGMP to sites A and B in the 
regulatory domain releases the inhibition of the catalytic center by the N-terminal 
autoinhibitory/pseudosubstrate site and allows the phosphorylation of Ser/Thr residues in 
the N-terminal autophosphorylation site and in target proteins. Other mechanisms of PKG 
activation include disulfide formation through hydrogen peroxide or heavy metals 
(Burgoyne et al., 2007; Landgraf et al., 1991), proteolytic cleavage of an N-terminal 77-
amino acid peptide (Landgraf and Hofmann, 1989; Scholten et al., 2007), or 
phosphorylation events in the N-terminus (Chu et al., 1998; Smith et al., 1996). 
 
Tissue specific distribution of PKG I (α and β) and PKG II 
High concentrations (> 0.1 µM) of PKG I are expressed in all smooth muscle, 
platelets, dorsal root ganglia, cerebellum, hippocampus, neuromuscular endplate and 
kidney (Geiselhoringer et al., 2004). Lower concentrations have been detected in cardiac 
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muscle, vascular endothelium, chondrocytes, osteoclasts and granulocytes. PKG I α is 
predominantly expressed in lung, heart, dorsal root ganglia and cerebellum, whereas 
hippocampal neurons, olfactory bulb neurons and platelets contain mainly PKG I β. Both 
isozymes have been identified in smooth muscle cells of the uterus, blood vessels, 
intestines and trachea. PKG II is expressed predominantly in the intestinal mucosa, brain 
nuclei, kidney, adrenal cortex, chondrocytes and lung (de Vente et al., 2001; el-Husseini 
et al., 1995; Vaandrager et al., 1998; Werner et al., 2004). 
 
Physiological roles of PKG II 
Most of our knowledge about the physiological roles of PKG II is derived from 
PKG II- deficient mice. These studies have shown that PKG II plays an important role in 
secretion as well as other cellular processes. PKG II is highly expressed in enterocytes of 
the small intestine, where it activates the cystic fibrosis transmembrane conductance 
regulator, thereby increasing Cl- and water secretion (Pfeifer et al., 1996; Vaandrager et 
al., 2000). Furthermore, PKG II is essential for natriuretic-peptide/cGMP-mediated 
endochondral ossification (Miyazawa et al., 2002) and regulates autonomous bone 
growth. Studies with PKG II- deficient mice confirmed that PKG II is also involved in 
the regulation of the circadian clock (Tischkau et al., 2003). In addition, deletion of PKG 
II resulted in mild neurological defects, such as a moderately enhanced anxiety-like 
behavior and a hyposensitivity to acute alcohol intake (Werner et al., 2004). 
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Physiological roles of PKG I α and β 
In contrast to PKG II, the major physiological roles of PKG I include regulation 
of vascular smooth muscle tone, smooth muscle proliferation and platelet aggregation.  
 
Platelet Aggregation 
Aggregation of platelets is initiated at areas where the endothelial cell layer has 
been destroyed. Endothelial cells release prostacyclin and NO, consequently raising 
cAMP and cGMP levels in platelets which thereby prevent clot formation. PKG I is 
expressed at high levels in platelets and has an anti-aggregatory function (Gambaryan et 
al., 2004; Marshall et al., 2004; Massberg et al., 1999). An intact platelet NO/PKG I 
signaling pathway is essential to prevent platelet aggregation after ischemia in vivo 
(Massberg et al., 1999). Platelets contain two well established PKG I substrates, VASP 
and IRAG. Deletion of the VASP gene in mice did not grossly affect platelet aggregation 
(Aszodi et al., 1999; Hauser et al., 1999), but considerably affected the interaction of 
platelets with the endothelium in vivo (Massberg et al., 2004). Activation of PKG I 
inhibited the release of Ca2+ from IP3-sensitive stores in wild type and VASP-deficient 
platelets to similar extents (Aszodi et al., 1999). Furthermore, platelets from the IRAG 
mutant mice have a severe defect in the cGMP-mediated prevention of aggregation 
indicating that IRAG is an essential component of this pathway (Geiselhoringer et al., 
2004). 
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Regulation of Smooth Muscle Proliferation 
NO, ANP, and cGMP analogs have been shown to prevent proliferation, 
migration, and dedifferentiation of vascular smooth muscle cells (Calderone et al., 1998; 
Garg and Hassid, 1989). Recent studies suggest that PKG I modulates gene expression 
through the extracellular signal-regulated kinase/mitogen-activated protein kinase 
pathway (Hofmann et al., 2000; Pilz and Casteel, 2003). VASP, an actin-binding protein 
localized at the focal adhesion and cell-to-cell contacts in many cells, is differentially 
phosphorylated by protein kinase C, cAMP kinase, and PKG I, and might be a key player 
in this signaling cascade (Chen et al., 2004).  
 
Regulation of vascular smooth muscle tone 
In general, smooth muscle tone is regulated by the rise and fall of intracellular 
calcium, [Ca2+]i. The rise of [Ca
2+]i is initiated either by receptor-mediated generation of 
inositol triphosphate (IP3) that releases Ca
2+ from intracellular stores or by an influx of 
extracellular Ca2+ through voltage-dependent Ca2+ channels (Moosmang et al., 2003). 
This rise in [Ca2+]i initiates contraction by activation of the Ca
2+/calmodulin-dependent 
myosin light chain kinase (MLCK), which phosphorylates the regulatory light chain 
(RLC) and, consequently, activates myosin ATPase. A decrease in [Ca2+]i deactivates 
MLCK, allowing for dephosphorylation of RLC by myosin light chain phosphatase 
(MLCP) (Surks et al., 1999). Smooth muscle contraction is also modulated at constant 
[Ca2+]i by changing the sensitivity of the contractile machinery to [Ca
2+]i (Somlyo and 
Somlyo, 2003). PKG I interferes both with the increase in [Ca2+]i and with the Ca
2+ 
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sensitivity through phosphorylation of IRAG, Ca2+-activated maxi-K+ (BKCa) channels, 
phospholamban (Koller et al., 2003; Porter et al., 1998; Robertson et al., 1993) and 
MLCP (Figure 1).  
One mechanism to lower [Ca2+]i is the PKG I-dependent phosphorylation of 
IRAG. IRAG is expressed at the endoplasmic reticulum membrane in smooth muscle, 
platelets, and some neurons, and interacts specifically with the leucine zipper of PKG I 
and with the IP3 receptor type I (Ammendola et al., 2001; Geiselhoringer et al., 2004). 
Studies on IRAG-deficient mice revealed that PKG I-dependent phosphorylation of 
IRAG inhibits IP3-induced Ca
2+ release (Geiselhoringer et al., 2004). Additionally, PKG I 
lowers [Ca2+]i through direct phosphorylation of BKCa channels (Robertson et al., 1993). 
Opening of BKCa channels hyperpolarizes the membrane and closes L-type calcium 
channels, thereby reducing Ca2+ influx. This mechanism contributes to the regulation of 
vascular tone, as shown in wild type and PKG I-deficient mice (Sausbier et al., 2000). An 
alternative mechanism to regulate smooth muscle tone is the PKG I dependent 
phosphorylation and activation of MLCP (Etter et al., 2001). Consequently, RLC 
phosphorylation is reduced and smooth muscle relaxed at constant [Ca2+]i. 
 
Detection of [cGMP]i using fluorescent indicators 
cGMP is a key signaling molecule for regulating vascular smooth muscle tone. In 
the past, [cGMP]i has been detected utilizing techniques such as guanylyl cyclase assays 
(Domino et al., 1991), radio-immunoassays (Brooker et al., 1979), patch cramming 
(Trivedi and Kramer, 1998) and patch clamping (Castro et al., 2006). However, the 
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dynamic rise and fall of [cGMP]i in living cells could not be monitored directly until the 
development of fluorescent cGMP biosensors (Honda et al., 2001; Nikolaev et al., 2006; 
Russwurm et al., 2007). In recent years, several fluorescence resonance energy transfer 
(FRET) - based indicators for cGMP have been reported, all of which utilize the general 
strategy of placing a conformationally sensitive cGMP binding domain between two 
mutants of green fluorescent protein (GFP) to modulate FRET. In 2001, Honda and 
colleagues were the first to report the successful development of FRET-based cGMP 
biosensors, called cygnets, by inserting a kinase inactive deletion fragment of cGMP-
dependent protein kinase (PKG) between cyan (CFP) and yellow (YFP) mutants of green 
fluorescent protein (Honda et al., 2001). cGMP binding to Cygnets decreased FRET and 
increased the overall ratio of cyan to yellow emissions by up to 1.5-fold for recombinant 
protein. Recombinant cygnets are also highly selective (>100 fold) for cGMP over cAMP 
with apparent KD values ranging from 0.6 to 1.9 µM (Honda et al., 2001; Honda et al., 
2005), (Table 1). Cygnets have revealed transient cGMP kinetics resulting from sGC 
activation by NO in rat fetal lung fibroblast (RFL)-6 cells, in Purkinje neurons (Honda et 
al., 2001) and in cultured, unpassaged rat aortic VSM cells (Cawley et al., 2007). Reports 
on the next set of FRET-based cGMP indicators followed in 2006, when isolated 
nucleotide binding domains, such as the single cGMP-binding domain B from PKG I or 
the single regulatory GAF domain from PDEs, were sandwiched between CFP and YFP 
(Nikolaev et al., 2006). These new indicators displayed cGMP affinities in the low 
micromolar range (Table 1) and had moderate (100 fold; PKG/PDE2-based) to high (400 
to 600 fold; PDE5-based) cGMP selectivity. In HEK cells, the sensors based on a single 
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PDE-GAF domain produced maximal 1.3 fold increase in FRET ratio and rapid 
responsiveness to NO-induced sGC activation. In 2007, Russwurm and colleagues 
reported the latest FRET-cGMP biosensors based on cyclic nucleotide binding sites of 
PKG I (Russwurm et al., 2007). Interestingly, only cGMP-binding domains arranged in 
tandem configuration as in their native configuration were cGMP-responsive. These new 
sensors produced an overall 1.6 to 1.7-fold increase in FRET ratio for recombinant 
protein upon cGMP binding, high cGMP affinities (0.5 to 6 µM), high cGMP selectivity 
and fast cGMP binding kinetics (Table 1).  
While the above mentioned cGMP biosensors have advanced our understanding 
of cGMP signaling, they all have some intrinsic limitations. For example, in living cells, 
all FRET based cGMP indicators display significantly decreased FRET ratios (maximal 
1.3 fold FRET ratio change), possibly due to interactions with endogenous proteins (such 
as PKGs and PDEs), as well as unspecific interactions caused by CFP and YFP. Due to 
these overall low FRET ratios, FRET-based indicators are not suitable for transgenic 
mouse models and hence are limited in their use to follow [cGMP]i dynamics in 
physiological systems. Furthermore, FRET-based indicators are unable to detect cGMP 
dynamics in response to physiological, low-nanomolar NO concentrations. In addition, 
FRET-based cGMP indicators are limited in their use for real-time, confocal imaging 
techniques and therefore have limited use to study real-time [cGMP]i dynamics in 
microdomains of living cells. These limitations prompted us to develop a new generation 
of non-FRET cGMP biosensors (Chapter 4), called FlincGs, suitable to monitor [cGMP]i 
in response to physiological (low-nanomolar) NO concentrations. In addition, FlincGs are 
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powerful tools to study [cGMP]i dynamics in response to various stimuli, by utilizing 
high-resolution, real-time confocal microscopy. FlincG-type biosensors are derived from 
the cGMP-receptor domains of PKG.  Thus, it has been necessary to characterize the 
molecular mechanism and the cGMP binding dynamics underlying PKG activation 
(Chapters 2 and 3). 
 
Focus of Dissertation 
Regulation of vascular smooth muscle tone is one of the major functions of 
cGMP-dependent protein kinase I. To investigate in detail cGMP-dependent PKG 
activation, we introduced several site-specific mutations in the regulatory cGMP binding 
domain and studied their effects on cGMP binding, dissociation and kinase activity 
(Chapter 2). We further attempted to crystallize full-length and deletion fragments of 
PKG to gain more insight into PKG structure and function (Chapter 3). Based on these 
studies, we developed a new generation of PKG-derived, non-FRET cGMP biosensors to 
examine the spatial distribution of [cGMP]i in response to NO and ANP in cultured VSM 
cells (Chapter 4) as well as in intact cerebral arteries (Chapter 5). These novel indicators 
for cGMP allow for investigation of the complex cross-talk between cGMP and calcium, 
and in addition, might be suitable for the development of transgenic mice with tissue-
specific expression of cGMP biosensors. 
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Table 1: Kinetic characteristics of different cGMP biosensors in vitro and in living cells 
 
Sensor  Backbone EC50,cGMP [µM] 
EC50, cAMP
[µM] cGMP/cAMP
1 (F/F0)max
2 (F/F0)max
3 Reference 
Cygnet 2.1 PKG I α (78-671) 1.7 > 1,000 > 600 1.5 1.3 (Honda et al., 2001) 
cGES-
GKIB 
PKG I B-site 5.0 486 97 - 1.3 (Nikolaev et al., 2006) 
cGES-DE2 PDE2A GAF-B site 0.9 115 128 - 1.3  
cGES-DE5 PDE5A GAF-B site 1.5 630 420 - 1.3  
cGi-500 PKG I α (79-345) 0.5 - - 1.7 1.3 (Russwurm et al., 2007) 
cGi-3000 PKG I α (79-336) 3      
      
 
- - 1.7 1.3
cGi-6000 PKG I α (79-328) 6 - - 1.6 1.3
α-FlincG PKG I α (1-356) 0.035 40 1140 1.5 1.2 (Nausch et al, Chapter 4) 
β-FlincG       
       
PKG I β (1-372) 1.1 31 30 2.1 1.2
δ-FlincG PKG I α (77-356) 0.17 48 280 1.7 1.7
 
1: Selectivity; 2: determined for recombinant protein; 3: determined in living cells;
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Figure legends: 
 
Figure 1: Overview of cGMP signaling in VSM cells. cGMP is synthesized by soluble 
guanylyl cyclases (sGC) in response to nitric oxide (NO), or by particulate, membrane 
bound guanylyl cyclases (GC-A/B) in response to natriuretic peptides (ANP, CNP). 
Physiological effects of cGMP are mediated through the action of phosphodiesterases 
(PDEs) and cGMP dependent protein kinases (PKGs), by phosphorylating IRAG, 
phospholamban (PL), myosin light chain phosphatase (MLCP) or Ca2+-activated maxi-K+ 
(BKCa) channels. Adapted from (Hofmann, 2005). 
 
Figure 2: GTP conversion into cGMP and pyrophosphate (PPi) is catalyzed by guanylyl 
cyclases (GC), while cGMP hydrolysis is mediated by phosphodiesterases (PDE). 
Chemical structures were created with the program ChemSketch. 
 
Figure 3: Atrial Natriuretic Peptide (ANP) secretion from the atrium. Adapted from 
(Dietz, 2005; Gardner et al., 2007; Ruskoaho, 1992). 
 
Figure 4: Nitric Oxide (NO) synthesis and release from vascular endothelium. Adapted 
from (Albrecht et al., 2003). 
 
Figure 5: General domain structure of dimeric receptor (rGC) and soluble (sGC) guanylyl 
cyclases. The receptor architecture consists of the extracellular domain (BCD), 
transmembrane segment (TM), kinase homology domain (KHD), coiled-coil domain 
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(CCD) and guanylyl cyclase domain (GC). The heterodimeric soluble guanylyl cyclase 
consists of a heme domain (HD), a CC and a GC domain. Adapted from (Fitzpatrick et 
al., 2006). 
  
Figure 6: Domain structure of PKG I α. Inset: The alpha-helical, N-terminal dimerization 
region is the only domain for which a structure has been determined (Schnell et al., 
2005). 
 
 19
Figure 1: 
 
 
 
 
 20
Figure 2: 
 
 21
Figure 3: 
 
 
 22
Figure 4: 
 
 23
Figure 5: 
 
 
 
 24
Figure 6: 
 
 
 25
References 
Albrecht EW, Stegeman CA, Heeringa P, Henning RH and van Goor H. Protective 
role of endothelial nitric oxide synthase. J Pathol 199(1): 8-17, 2003. 
 
Ammendola A, Geiselhoringer A, Hofmann F and Schlossmann J. Molecular 
determinants of the interaction between the inositol 1,4,5-trisphosphate receptor-
associated cGMP kinase substrate (IRAG) and cGMP kinase Ibeta. J Biol Chem 276(26): 
24153-9, 2001. 
 
Aszodi A, Pfeifer A, Ahmad M, Glauner M, Zhou XH, Ny L, Andersson KE, Kehrel 
B, Offermanns S and Fassler R. The vasodilator-stimulated phosphoprotein (VASP) is 
involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet 
aggregation, but is dispensable for smooth muscle function. Embo J 18(1): 37-48, 1999. 
 
Ballou DP, Zhao Y, Brandish PE and Marletta MA. Revisiting the kinetics of nitric 
oxide (NO) binding to soluble guanylate cyclase: the simple NO-binding model is 
incorrect. Proc Natl Acad Sci U S A 99(19): 12097-101, 2002. 
 
Brooker G, Harper JF, Terasaki WL and Moylan RD. Radioimmunoassay of cyclic 
AMP and cyclic GMP. Adv Cyclic Nucleotide Res 10: 1-33, 1979. 
 
Burgoyne JR, Madhani M, Cuello F, Charles RL, Brennan JP, Schroder E, 
Browning DD and Eaton P. Cysteine redox sensor in PKGIa enables oxidant-induced 
activation. Science 317(5843): 1393-7, 2007. 
 
Calderone A, Thaik CM, Takahashi N, Chang DL and Colucci WS. Nitric oxide, 
atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of 
norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest 101(4): 812-8, 1998. 
 
Cary SP, Winger JA, Derbyshire ER and Marletta MA. Nitric oxide signaling: no 
longer simply on or off. Trends Biochem Sci 31(4): 231-9, 2006. 
 
Castro LR, Verde I, Cooper DM and Fischmeister R. Cyclic guanosine 
monophosphate compartmentation in rat cardiac myocytes. Circulation 113(18): 2221-8, 
2006. 
 
Cawley SM, Sawyer CL, Brunelle KF, van der Vliet A and Dostmann WR. Nitric 
oxide-evoked transient kinetics of cyclic GMP in vascular smooth muscle cells. Cell 
Signal 19(5): 1023-33, 2007. 
 
Cha B, Kim JH, Hut H, Hogema BM, Nadarja J, Zizak M, Cavet M, Lee-Kwon W, 
Lohmann SM, Smolenski A, Tse CM, Yun C, de Jonge HR and Donowitz M. cGMP 
inhibition of Na+/H+ antiporter 3 (NHE3) requires PDZ domain adapter NHERF2, a 
 26
broad specificity protein kinase G-anchoring protein. J Biol Chem 280(17): 16642-50, 
2005. 
 
Chen L, Daum G, Chitaley K, Coats SA, Bowen-Pope DF, Eigenthaler M, Thumati 
NR, Walter U and Clowes AW. Vasodilator-stimulated phosphoprotein regulates 
proliferation and growth inhibition by nitric oxide in vascular smooth muscle cells. 
Arterioscler Thromb Vasc Biol 24(8): 1403-8, 2004. 
 
Chinkers M and Garbers DL. The protein kinase domain of the ANP receptor is 
required for signaling. Science 245(4924): 1392-4, 1989. 
 
Chu DM, Francis SH, Thomas JW, Maksymovitch EA, Fosler M and Corbin JD. 
Activation by autophosphorylation or cGMP binding produces a similar apparent 
conformational change in cGMP-dependent protein kinase. J Biol Chem 273(23): 14649-
56, 1998. 
 
Chusho H, Tamura N, Ogawa Y, Yasoda A, Suda M, Miyazawa T, Nakamura K, 
Nakao K, Kurihara T, Komatsu Y, Itoh H, Tanaka K, Saito Y, Katsuki M and 
Nakao K. Dwarfism and early death in mice lacking C-type natriuretic peptide. Proc 
Natl Acad Sci U S A 98(7): 4016-21, 2001. 
 
Conti M and Beavo J. Biochemistry and physiology of cyclic nucleotide 
phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev 
Biochem 76: 481-511, 2007. 
 
Corbin JD, Turko IV, Beasley A and Francis SH. Phosphorylation of 
phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and 
allosteric cGMP-binding activities. Eur J Biochem 267(9): 2760-7, 2000. 
 
de Bold AJ, Borenstein HB, Veress AT and Sonnenberg H. A rapid and potent 
natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 
28(1): 89-94, 1981. 
 
de Bold AJ, Ma KK, Zhang Y, de Bold ML, Bensimon M and Khoshbaten A. The 
physiological and pathophysiological modulation of the endocrine function of the heart. 
Can J Physiol Pharmacol 79(8): 705-14, 2001. 
 
de Vente J, Asan E, Gambaryan S, Markerink-van Ittersum M, Axer H, Gallatz K, 
Lohmann SM and Palkovits M. Localization of cGMP-dependent protein kinase type II 
in rat brain. Neuroscience 108(1): 27-49, 2001. 
 
Dietz JR. Mechanisms of atrial natriuretic peptide secretion from the atrium. Cardiovasc 
Res 68(1): 8-17, 2005. 
 
 27
Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R and Zeiher AM. 
Activation of nitric oxide synthase in endothelial cells by Akt-dependent 
phosphorylation. Nature 399(6736): 601-5, 1999. 
 
Domino SE, Tubb DJ and Garbers DL. Assay of guanylyl cyclase catalytic activity. 
Methods Enzymol 195: 345-55, 1991. 
 
el-Husseini AE, Bladen C and Vincent SR. Molecular characterization of a type II 
cyclic GMP-dependent protein kinase expressed in the rat brain. J Neurochem 64(6): 
2814-7, 1995. 
 
Erwin PA, Lin AJ, Golan DE and Michel T. Receptor-regulated dynamic S-
nitrosylation of endothelial nitric-oxide synthase in vascular endothelial cells. J Biol 
Chem 280(20): 19888-94, 2005. 
 
Etter EF, Eto M, Wardle RL, Brautigan DL and Murphy RA. Activation of myosin 
light chain phosphatase in intact arterial smooth muscle during nitric oxide-induced 
relaxation. J Biol Chem 276(37): 34681-5, 2001. 
 
Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HH and Stasch JP. NO-
independent stimulators and activators of soluble guanylate cyclase: discovery and 
therapeutic potential. Nat Rev Drug Discov 5(9): 755-68, 2006. 
 
Fitzpatrick DA, O'Halloran DM and Burnell AM. Multiple lineage specific 
expansions within the guanylyl cyclase gene family. BMC Evol Biol 6: 26, 2006. 
 
Francis SH, Blount MA, Zoraghi R and Corbin JD. Molecular properties of 
mammalian proteins that interact with cGMP: protein kinases, cation channels, 
phosphodiesterases, and multi-drug anion transporters. Front Biosci 10: 2097-117, 2005. 
 
Francis SH and Corbin JD. Cyclic nucleotide-dependent protein kinases: intracellular 
receptors for cAMP and cGMP action. Crit Rev Clin Lab Sci 36(4): 275-328, 1999. 
 
Friebe A, Mergia E, Dangel O, Lange A and Koesling D. Fatal gastrointestinal 
obstruction and hypertension in mice lacking nitric oxide-sensitive guanylyl cyclase. 
Proc Natl Acad Sci U S A 104(18): 7699-704, 2007. 
 
Gambaryan S, Geiger J, Schwarz UR, Butt E, Begonja A, Obergfell A and Walter 
U. Potent inhibition of human platelets by cGMP analogs independent of cGMP-
dependent protein kinase. Blood 103(7): 2593-600, 2004. 
 
Garbers DL and Lowe DG. Guanylyl cyclase receptors. J Biol Chem 269(49): 30741-4, 
1994. 
 
 28
Gardner DG, Chen S, Glenn DJ and Grigsby CL. Molecular biology of the natriuretic 
peptide system: implications for physiology and hypertension. Hypertension 49(3): 419-
26, 2007. 
 
Garg UC and Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic 
guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular 
smooth muscle cells. J Clin Invest 83(5): 1774-7, 1989. 
 
Geiselhoringer A, Gaisa M, Hofmann F and Schlossmann J. Distribution of IRAG 
and cGKI-isoforms in murine tissues. FEBS Lett 575(1-3): 19-22, 2004. 
 
Geiselhoringer A, Werner M, Sigl K, Smital P, Worner R, Acheo L, Stieber J, 
Weinmeister P, Feil R, Feil S, Wegener J, Hofmann F and Schlossmann J. IRAG is 
essential for relaxation of receptor-triggered smooth muscle contraction by cGMP kinase. 
Embo J 23(21): 4222-31, 2004. 
 
Gopal VK, Francis SH and Corbin JD. Allosteric sites of phosphodiesterase-5 (PDE5). 
A potential role in negative feedback regulation of cGMP signaling in corpus 
cavernosum. Eur J Biochem 268(11): 3304-12, 2001. 
 
Gudi S, Nolan JP and Frangos JA. Modulation of GTPase activity of G proteins by 
fluid shear stress and phospholipid composition. Proc Natl Acad Sci U S A 95(5): 2515-9, 
1998. 
 
Hauser W, Knobeloch KP, Eigenthaler M, Gambaryan S, Krenn V, Geiger J, 
Glazova M, Rohde E, Horak I, Walter U and Zimmer M. Megakaryocyte hyperplasia 
and enhanced agonist-induced platelet activation in vasodilator-stimulated 
phosphoprotein knockout mice. Proc Natl Acad Sci U S A 96(14): 8120-5, 1999. 
 
Hofmann F. The biology of cyclic GMP-dependent protein kinases. J Biol Chem 280(1): 
1-4, 2005. 
 
Hofmann F, Ammendola A and Schlossmann J. Rising behind NO: cGMP-dependent 
protein kinases. J Cell Sci 113 ( Pt 10): 1671-6, 2000. 
 
Hofmann F, Biel M and Kaupp UB. International Union of Pharmacology. LI. 
Nomenclature and structure-function relationships of cyclic nucleotide-regulated 
channels. Pharmacol Rev 57(4): 455-62, 2005. 
 
Honda A, Adams SR, Sawyer CL, Lev-Ram V, Tsien RY and Dostmann WR. 
Spatiotemporal dynamics of guanosine 3',5'-cyclic monophosphate revealed by a 
genetically encoded, fluorescent indicator. Proc Natl Acad Sci U S A 98(5): 2437-42, 
2001. 
 
 29
Honda A, Sawyer CL, Cawley SM and Dostmann WR. Cygnets: in vivo 
characterization of novel cGMP indicators and in vivo imaging of intracellular cGMP. 
Methods Mol Biol 307: 27-43, 2005. 
 
Hwang TL, Wu CC and Teng CM. Comparison of two soluble guanylyl cyclase 
inhibitors, methylene blue and ODQ, on sodium nitroprusside-induced relaxation in 
guinea-pig trachea. Br J Pharmacol 125(6): 1158-63, 1998. 
 
Ignarro LJ, Adams JB, Horwitz PM and Wood KS. Activation of soluble guanylate 
cyclase by NO-hemoproteins involves NO-heme exchange. Comparison of heme-
containing and heme-deficient enzyme forms. J Biol Chem 261(11): 4997-5002, 1986. 
 
Iyer LM, Anantharaman V and Aravind L. Ancient conserved domains shared by 
animal soluble guanylyl cyclases and bacterial signaling proteins. BMC Genomics 4(1): 
5, 2003. 
 
John SW, Veress AT, Honrath U, Chong CK, Peng L, Smithies O and Sonnenberg 
H. Blood pressure and fluid-electrolyte balance in mice with reduced or absent ANP. Am 
J Physiol 271(1 Pt 2): R109-14, 1996. 
 
Joubert S, McNicoll N and De Lean A. Biochemical and pharmacological 
characterization of P-site inhibitors on homodimeric guanylyl cyclase domain from 
natriuretic peptide receptor-A. Biochem Pharmacol 73(7): 954-63, 2007. 
 
Kangawa K and Matsuo H. Purification and complete amino acid sequence of alpha-
human atrial natriuretic polypeptide (alpha-hANP). Biochem Biophys Res Commun 
118(1): 131-9, 1984. 
 
Kass DA, Takimoto E, Nagayama T and Champion HC. Phosphodiesterase regulation 
of nitric oxide signaling. Cardiovasc Res 75(2): 303-14, 2007. 
 
Koller A, Schlossmann J, Ashman K, Uttenweiler-Joseph S, Ruth P and Hofmann F. 
Association of phospholamban with a cGMP kinase signaling complex. Biochem Biophys 
Res Commun 300(1): 155-60, 2003. 
 
Koller KJ, de Sauvage FJ, Lowe DG and Goeddel DV. Conservation of the kinaselike 
regulatory domain is essential for activation of the natriuretic peptide receptor guanylyl 
cyclases. Mol Cell Biol 12(6): 2581-90, 1992. 
 
Komatsu Y, Itoh H, Suga S, Ogawa Y, Hama N, Kishimoto I, Nakagawa O, Igaki T, 
Doi K, Yoshimasa T and Nakao K. Regulation of endothelial production of C-type 
natriuretic peptide in coculture with vascular smooth muscle cells. Role of the vascular 
natriuretic peptide system in vascular growth inhibition. Circ Res 78(4): 606-14, 1996. 
 
 30
Kou R, Greif D and Michel T. Dephosphorylation of endothelial nitric-oxide synthase 
by vascular endothelial growth factor. Implications for the vascular responses to 
cyclosporin A. J Biol Chem 277(33): 29669-73, 2002. 
 
Kuhn M. Cardiac and intestinal natriuretic peptides: insights from genetically modified 
mice. Peptides 26(6): 1078-85, 2005. 
 
Kuhn M, Holtwick R, Baba HA, Perriard JC, Schmitz W and Ehler E. Progressive 
cardiac hypertrophy and dysfunction in atrial natriuretic peptide receptor (GC-A) 
deficient mice. Heart 87(4): 368-74, 2002. 
 
Landgraf W and Hofmann F. The amino terminus regulates binding to and activation 
of cGMP-dependent protein kinase. Eur J Biochem 181(3): 643-50, 1989. 
 
Landgraf W, Hofmann F, Pelton JT and Huggins JP. Effects of cyclic GMP on the 
secondary structure of cyclic GMP dependent protein kinase and analysis of the enzyme's 
amino-terminal domain by far-ultraviolet circular dichroism. Biochemistry 29(42): 9921-
8, 1990. 
 
Landgraf W, Regulla S, Meyer HE and Hofmann F. Oxidation of cysteines activates 
cGMP-dependent protein kinase. J Biol Chem 266(25): 16305-11, 1991. 
 
Leroy MJ, Degerman E, Taira M, Murata T, Wang LH, Movsesian MA, Meacci E 
and Manganiello VC. Characterization of two recombinant PDE3 (cGMP-inhibited 
cyclic nucleotide phosphodiesterase) isoforms, RcGIP1 and HcGIP2, expressed in NIH 
3006 murine fibroblasts and Sf9 insect cells. Biochemistry 35(31): 10194-202, 1996. 
 
Lin CS, Lin G, Xin ZC and Lue TF. Expression, distribution and regulation of 
phosphodiesterase 5. Curr Pharm Des 12(27): 3439-57, 2006. 
 
Liu Y, Ruoho AE, Rao VD and Hurley JH. Catalytic mechanism of the adenylyl and 
guanylyl cyclases: modeling and mutational analysis. Proc Natl Acad Sci U S A 94(25): 
13414-9, 1997. 
 
Lopez MJ, Wong SK, Kishimoto I, Dubois S, Mach V, Friesen J, Garbers DL and 
Beuve A. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for 
atrial natriuretic peptide. Nature 378(6552): 65-8, 1995. 
 
Ma X, Sayed N, Beuve A and van den Akker F. NO and CO differentially activate 
soluble guanylyl cyclase via a heme pivot-bend mechanism. Embo J 26(2): 578-88, 2007. 
 
MacMillan-Crow LA and Lincoln TM. High-affinity binding and localization of the 
cyclic GMP-dependent protein kinase with the intermediate filament protein vimentin. 
Biochemistry 33(26): 8035-43, 1994. 
 31
 
Marshall SJ, Senis YA, Auger JM, Feil R, Hofmann F, Salmon G, Peterson JT, 
Burslem F and Watson SP. GPIb-dependent platelet activation is dependent on Src 
kinases but not MAP kinase or cGMP-dependent kinase. Blood 103(7): 2601-9, 2004. 
 
Massberg S, Gruner S, Konrad I, Garcia Arguinzonis MI, Eigenthaler M, Hemler 
K, Kersting J, Schulz C, Muller I, Besta F, Nieswandt B, Heinzmann U, Walter U 
and Gawaz M. Enhanced in vivo platelet adhesion in vasodilator-stimulated 
phosphoprotein (VASP)-deficient mice. Blood 103(1): 136-42, 2004. 
 
Massberg S, Sausbier M, Klatt P, Bauer M, Pfeifer A, Siess W, Fassler R, Ruth P, 
Krombach F and Hofmann F. Increased adhesion and aggregation of platelets lacking 
cyclic guanosine 3',5'-monophosphate kinase I. J Exp Med 189(8): 1255-64, 1999. 
 
Mayer B and Koesling D. cGMP signalling beyond nitric oxide. Trends Pharmacol Sci 
22(11): 546-8, 2001. 
 
Mergia E, Friebe A, Dangel O, Russwurm M and Koesling D. Spare guanylyl cyclase 
NO receptors ensure high NO sensitivity in the vascular system. J Clin Invest 116(6): 
1731-7, 2006. 
 
Miyazawa T, Ogawa Y, Chusho H, Yasoda A, Tamura N, Komatsu Y, Pfeifer A, 
Hofmann F and Nakao K. Cyclic GMP-dependent protein kinase II plays a critical role 
in C-type natriuretic peptide-mediated endochondral ossification. Endocrinology 143(9): 
3604-10, 2002. 
 
Mo E, Amin H, Bianco IH and Garthwaite J. Kinetics of a cellular nitric 
oxide/cGMP/phosphodiesterase-5 pathway. J Biol Chem 279(25): 26149-58, 2004. 
 
Moncada S, Palmer RM and Higgs EA. Nitric oxide: physiology, pathophysiology, and 
pharmacology. Pharmacol Rev 43(2): 109-42, 1991. 
 
Montagnani M, Chen H, Barr VA and Quon MJ. Insulin-stimulated activation of 
eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179). J Biol 
Chem 276(32): 30392-8, 2001. 
 
Moosmang S, Schulla V, Welling A, Feil R, Feil S, Wegener JW, Hofmann F and 
Klugbauer N. Dominant role of smooth muscle L-type calcium channel Cav1.2 for blood 
pressure regulation. Embo J 22(22): 6027-34, 2003. 
 
Mullershausen F, Russwurm M, Thompson WJ, Liu L, Koesling D and Friebe A. 
Rapid nitric oxide-induced desensitization of the cGMP response is caused by increased 
activity of phosphodiesterase type 5 paralleled by phosphorylation of the enzyme. J Cell 
Biol 155(2): 271-8, 2001. 
 32
 
Nikolaev VO, Gambaryan S and Lohse MJ. Fluorescent sensors for rapid monitoring 
of intracellular cGMP. Nat Methods 3(1): 23-5, 2006. 
 
Nimmegeers S, Sips P, Buys E, Brouckaert P and Van de Voorde J. Functional role 
of the soluble guanylyl cyclase alpha(1) subunit in vascular smooth muscle relaxation. 
Cardiovasc Res 76(1): 149-59, 2007. 
 
Okada D and Asakawa S. Allosteric activation of cGMP-specific, cGMP-binding 
phosphodiesterase (PDE5) by cGMP. Biochemistry 41(30): 9672-9, 2002. 
 
Olesen SP, Drejer J, Axelsson O, Moldt P, Bang L, Nielsen-Kudsk JE, Busse R and 
Mulsch A. Characterization of NS 2028 as a specific inhibitor of soluble guanylyl 
cyclase. Br J Pharmacol 123(2): 299-309, 1998. 
 
Oliver PM, John SW, Purdy KE, Kim R, Maeda N, Goy MF and Smithies O. 
Natriuretic peptide receptor 1 expression influences blood pressures of mice in a dose-
dependent manner. Proc Natl Acad Sci U S A 95(5): 2547-51, 1998. 
 
Olivera A and Spiegel S. Sphingosine-1-phosphate as second messenger in cell 
proliferation induced by PDGF and FCS mitogens. Nature 365(6446): 557-60, 1993. 
 
Palmer RM, Ashton DS and Moncada S. Vascular endothelial cells synthesize nitric 
oxide from L-arginine. Nature 333(6174): 664-6, 1988. 
 
Pellicena P, Karow DS, Boon EM, Marletta MA and Kuriyan J. Crystal structure of 
an oxygen-binding heme domain related to soluble guanylate cyclases. Proc Natl Acad 
Sci U S A 101(35): 12854-9, 2004. 
 
Pfeifer A, Aszodi A, Seidler U, Ruth P, Hofmann F and Fassler R. Intestinal secretory 
defects and dwarfism in mice lacking cGMP-dependent protein kinase II. Science 
274(5295): 2082-6, 1996. 
 
Pfeifer A, Ruth P, Dostmann W, Sausbier M, Klatt P and Hofmann F. Structure and 
function of cGMP-dependent protein kinases. Rev Physiol Biochem Pharmacol 135: 105-
49, 1999. 
 
Pilz RB and Casteel DE. Regulation of gene expression by cyclic GMP. Circ Res 
93(11): 1034-46, 2003. 
 
Porter VA, Bonev AD, Knot HJ, Heppner TJ, Stevenson AS, Kleppisch T, Lederer 
WJ and Nelson MT. Frequency modulation of Ca2+ sparks is involved in regulation of 
arterial diameter by cyclic nucleotides. Am J Physiol 274(5 Pt 1): C1346-55, 1998. 
 
 33
Richie-Jannetta R, Busch JL, Higgins KA, Corbin JD and Francis SH. Isolated 
regulatory domains of cGMP-dependent protein kinase Ialpha and Ibeta retain 
dimerization and native cGMP-binding properties and undergo isoform-specific 
conformational changes. J Biol Chem 281(11): 6977-84, 2006. 
 
Robertson BE, Schubert R, Hescheler J and Nelson MT. cGMP-dependent protein 
kinase activates Ca-activated K channels in cerebral artery smooth muscle cells. Am J 
Physiol 265(1 Pt 1): C299-303, 1993. 
 
Ruskoaho H. Atrial natriuretic peptide: synthesis, release, and metabolism. Pharmacol 
Rev 44(4): 479-602, 1992. 
 
Russwurm M, Mullershausen F, Friebe A, Jager R, Russwurm C and Koesling D. 
Design of fluorescence resonance energy transfer (FRET)-based cGMP indicators: a 
systematic approach. Biochem J 407(1): 69-77, 2007. 
 
Ruth P, Landgraf W, Keilbach A, May B, Egleme C and Hofmann F. The activation 
of expressed cGMP-dependent protein kinase isozymes I alpha and I beta is determined 
by the different amino-termini. Eur J Biochem 202(3): 1339-44, 1991. 
 
Rybalkin SD, Rybalkina IG, Shimizu-Albergine M, Tang XB and Beavo JA. PDE5 is 
converted to an activated state upon cGMP binding to the GAF A domain. Embo J 22(3): 
469-78, 2003. 
 
Sausbier M, Schubert R, Voigt V, Hirneiss C, Pfeifer A, Korth M, Kleppisch T, 
Ruth P and Hofmann F. Mechanisms of NO/cGMP-dependent vasorelaxation. Circ Res 
87(9): 825-30, 2000. 
 
Schindler U, Strobel H, Schonafinger K, Linz W, Lohn M, Martorana PA, Rutten 
H, Schindler PW, Busch AE, Sohn M, Topfer A, Pistorius A, Jannek C and Mulsch 
A. Biochemistry and pharmacology of novel anthranilic acid derivatives activating heme-
oxidized soluble guanylyl cyclase. Mol Pharmacol 69(4): 1260-8, 2006. 
 
Schnell JR, Zhou GP, Zweckstetter M, Rigby AC and Chou JJ. Rapid and accurate 
structure determination of coiled-coil domains using NMR dipolar couplings: application 
to cGMP-dependent protein kinase Ialpha. Protein Sci 14(9): 2421-8, 2005. 
 
Scholten A, Fuss H, Heck AJ and Dostmann WR. The hinge region operates as a 
stability switch in cGMP-dependent protein kinase I alpha. Febs J 274(9): 2274-86, 2007. 
 
Schrammel A, Behrends S, Schmidt K, Koesling D and Mayer B. Characterization of 
1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-
sensitive guanylyl cyclase. Mol Pharmacol 50(1): 1-5, 1996. 
 
 34
Smith JA, Francis SH, Walsh KA, Kumar S and Corbin JD. Autophosphorylation of 
type Ibeta cGMP-dependent protein kinase increases basal catalytic activity and enhances 
allosteric activation by cGMP or cAMP. J Biol Chem 271(34): 20756-62, 1996. 
 
Somlyo AP and Somlyo AV. Ca2+ sensitivity of smooth muscle and nonmuscle myosin 
II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 83(4): 1325-
58, 2003. 
 
Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, H SA, Meurer S, Deile M, 
Taye A, Knorr A, Lapp H, Muller H, Turgay Y, Rothkegel C, Tersteegen A, Kemp-
Harper B, Muller-Esterl W and Schmidt HH. Targeting the heme-oxidized nitric 
oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest 116(9): 
2552-61, 2006. 
 
Steinhelper ME, Cochrane KL and Field LJ. Hypotension in transgenic mice 
expressing atrial natriuretic factor fusion genes. Hypertension 16(3): 301-7, 1990. 
 
Sudoh T, Kangawa K, Minamino N and Matsuo H. A new natriuretic peptide in 
porcine brain. Nature 332(6159): 78-81, 1988. 
 
Sudoh T, Minamino N, Kangawa K and Matsuo H. C-type natriuretic peptide (CNP): 
a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys 
Res Commun 168(2): 863-70, 1990. 
 
Surks HK, Mochizuki N, Kasai Y, Georgescu SP, Tang KM, Ito M, Lincoln TM and 
Mendelsohn ME. Regulation of myosin phosphatase by a specific interaction with 
cGMP- dependent protein kinase Ialpha. Science 286(5444): 1583-7, 1999. 
 
Tamura N, Doolittle LK, Hammer RE, Shelton JM, Richardson JA and Garbers 
DL. Critical roles of the guanylyl cyclase B receptor in endochondral ossification and 
development of female reproductive organs. Proc Natl Acad Sci U S A 101(49): 17300-5, 
2004. 
 
Thomas MK, Francis SH and Corbin JD. Substrate- and kinase-directed regulation of 
phosphorylation of a cGMP-binding phosphodiesterase by cGMP. J Biol Chem 265(25): 
14971-8, 1990. 
 
Tischkau SA, Weber ET, Abbott SM, Mitchell JW and Gillette MU. Circadian clock-
controlled regulation of cGMP-protein kinase G in the nocturnal domain. J Neurosci 
23(20): 7543-50, 2003. 
 
Trivedi B and Kramer RH. Real-time patch-cram detection of intracellular cGMP 
reveals long-term suppression of responses to NO and muscarinic agonists. Neuron 21(4): 
895-906, 1998. 
 35
 
Turko IV, Francis SH and Corbin JD. Binding of cGMP to both allosteric sites of 
cGMP-binding cGMP-specific phosphodiesterase (PDE5) is required for its 
phosphorylation. Biochem J 329 ( Pt 3): 505-10, 1998. 
 
Vaandrager AB, Bot AG, Ruth P, Pfeifer A, Hofmann F and De Jonge HR. 
Differential role of cyclic GMP-dependent protein kinase II in ion transport in murine 
small intestine and colon. Gastroenterology 118(1): 108-14, 2000. 
 
Vaandrager AB, Smolenski A, Tilly BC, Houtsmuller AB, Ehlert EM, Bot AG, 
Edixhoven M, Boomaars WE, Lohmann SM and de Jonge HR. Membrane targeting 
of cGMP-dependent protein kinase is required for cystic fibrosis transmembrane 
conductance regulator Cl- channel activation. Proc Natl Acad Sci U S A 95(4): 1466-71, 
1998. 
 
Vaandrager AB, Tilly BC, Smolenski A, Schneider-Rasp S, Bot AG, Edixhoven M, 
Scholte BJ, Jarchau T, Walter U, Lohmann SM, Poller WC and de Jonge HR. 
cGMP stimulation of cystic fibrosis transmembrane conductance regulator Cl- channels 
co-expressed with cGMP-dependent protein kinase type II but not type Ibeta. J Biol 
Chem 272(7): 4195-200, 1997. 
 
Wall ME, Francis SH, Corbin JD, Grimes K, Richie-Jannetta R, Kotera J, 
Macdonald BA, Gibson RR and Trewhella J. Mechanisms associated with cGMP 
binding and activation of cGMP-dependent protein kinase. Proc Natl Acad Sci U S A 
100(5): 2380-5, 2003. 
 
Werner C, Raivich G, Cowen M, Strekalova T, Sillaber I, Buters JT, Spanagel R 
and Hofmann F. Importance of NO/cGMP signalling via cGMP-dependent protein 
kinase II for controlling emotionality and neurobehavioural effects of alcohol. Eur J 
Neurosci 20(12): 3498-506, 2004. 
 
Wilson EM and Chinkers M. Identification of sequences mediating guanylyl cyclase 
dimerization. Biochemistry 34(14): 4696-701, 1995. 
 
Winger JA and Marletta MA. Expression and characterization of the catalytic domains 
of soluble guanylate cyclase: interaction with the heme domain. Biochemistry 44(10): 
4083-90, 2005. 
 
Yamahara K, Itoh H, Chun TH, Ogawa Y, Yamashita J, Sawada N, Fukunaga Y, 
Sone M, Yurugi-Kobayashi T, Miyashita K, Tsujimoto H, Kook H, Feil R, Garbers 
DL, Hofmann F and Nakao K. Significance and therapeutic potential of the natriuretic 
peptides/cGMP/cGMP-dependent protein kinase pathway in vascular regeneration. Proc 
Natl Acad Sci U S A 100(6): 3404-9, 2003. 
 
 36
Zabel U, Weeger M, La M and Schmidt HH. Human soluble guanylate cyclase: 
functional expression and revised isoenzyme family. Biochem J 335 ( Pt 1): 51-7, 1998. 
 
Zhao J, Trewhella J, Corbin J, Francis S, Mitchell R, Brushia R and Walsh D. 
Progressive cyclic nucleotide-induced conformational changes in the cGMP-dependent 
protein kinase studied by small angle X-ray scattering in solution. J Biol Chem 272(50): 
31929-36, 1997. 
 
Zhao Y, Brandish PE, Ballou DP and Marletta MA. A molecular basis for nitric oxide 
sensing by soluble guanylate cyclase. Proc Natl Acad Sci U S A 96(26): 14753-8, 1999. 
 
Zhao Y, Brandish PE, DiValentin M, Schelvis JP, Babcock GT and Marletta MA. 
Inhibition of soluble guanylate cyclase by ODQ. Biochemistry 39(35): 10848-54, 2000. 
 
 
 
 37
CHAPTER TWO: CYCLIC NUCLEOTIDE BINDING SITE MUTATIONS 
DELINEATE THE MECHANISM OF cGMP-DEPENDENT PROTEIN KINASE 
Iα ACTIVATION 
 
Lydia WM Nausch, Xuguang Yan*, Claudia S Maier*, Christian K Nickl and Wolfgang 
R Dostmann 
 
Department of Pharmacology, University of Vermont, College of Medicine, Burlington, 
05405 VT 
* Department of Chemistry, Oregon State University, Corvallis, 97330 OR  
 
Corresponding author: Wolfgang Dostmann, Ph.D, University of Vermont, Department 
of Pharmacology, Health Science Research Facility 330, 149 Beaumont Avenue, 
Burlington, VT 05405-0075, USA 
Tel: (802) 656-0381, Fax: (802) 656-4523, EMail: wdostman@uvm.edu 
 
Submitted to Biochemistry 
 38
Abstract 
Binding of cGMP manifests the central allosteric mechanism of activation for the 
homo-dimeric cGMP-dependent protein kinase Iα (PKG). The relative contributions of 
the two in-tandem cGMP binding sites A and B in the enzyme’s mechanism of activation 
are not known, however. Based on homology models derived from cAMP-dependent 
protein kinases (PKA), we introduced the loss-of-function mutations G167E, E168G, 
R177K and G291E, E292G, R301K in each cGMP binding site A and B, respectively. 
Surprisingly, the arginine to lysine mutations (R177K, R301K) retained cGMP binding to 
both sites. Their differentially shifted activation constants of 620 nM (site A) and 16 nM 
(site B) support a hitherto unknown dominant role of site B in modulating the phenotype 
of PKG activation. In accordance to the homology models, the glycine and glutamate 
mutations fully blocked cGMP binding to either site A or B. In contrast to PKA however, 
both site A loss-of-function mutants (G167E, E168G) were unexpectedly cGMP-
insensitive, demonstrating constitutively elevated kinase activities. Equally unanticipated, 
the equivalent site B loss-of-function mutants (G291E, E292G), as well as the R301K 
mutant, showed intact cGMP-dependency of kinase activity characterized by decreased 
cGMP-sensitivities. These findings suggest a) juxtaposed orientation of low and high 
affinity cGMP binding sites in PKG Iα, compared to PKA Iα, and b) functional coupling 
between cGMP binding site A and the catalytic domain. Taken together, we propose a 
previously unrecognized concerted mechanism of PKG I α.   
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Introduction 
The type Iα/Iβ and type II cGMP dependent protein kinases (PKGs) are members 
of the cyclic nucleotide-dependent serine/threonine protein kinases with closest sequence 
homologies to the type Iα/Iβ and type IIα/IIβ cyclic AMP dependent protein kinases 
(PKAs) (Francis and Corbin, 1994; Pfeifer et al., 1999; Scott, 1991). Although both 
kinase sub-families possess regulatory domains that modulate the accessibility of 
substrates to the catalytic domain, they differ in key architectural aspects that contribute 
to their respective mechanisms of activation. The tetrameric PKA holoenzymes are 
composed of two regulatory subunits (R2) associated with two catalytic subunits 
(Brostrom et al., 1971; Gill and Garren, 1971; Reimann et al., 1971). The R2 subunits 
inhibit kinase activity through the association of their autoinhibitory region with the 
catalytic subunit (Brostrom et al., 1971; Erlichman et al., 1973; Kemp et al., 1975; Taylor 
and Stafford, 1978). Binding of cAMP to the R2 subunits causes the tetramer to dissociate 
and thus releases inhibition of the catalytic subunit. The PKG holoenzymes are composed 
differently: they consist of dimers of two identical subunits, with each subunit possessing 
a regulatory and catalytic domain (Gill et al., 1976; Lincoln et al., 1977; Monken and 
Gill, 1980; Takio et al., 1984). For each monomer, the catalytic and regulatory domains 
are located on one polypeptide chain and thus cGMP binding cannot induce dissociation 
of the catalytic domain from the holoenzyme.  
Another notable characteristic for cyclic nucleotide kinases is their distinct 
structural order of high and low affinity cyclic nucleotide binding sites relative to the N-
terminus (Doskeland et al., 1987; Ogreid and Doskeland, 1980; Ogreid and Doskeland, 
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1981; Ogreid et al., 1983). For PKG I β, the slow nucleotide dissociation site is closer to 
the N-terminus than the fast dissociation site (Reed et al., 1996), whereas for PKA I, 
PKA II and PKG II, the fast dissociation site is closer to the N-terminus (Bubis and 
Taylor, 1987; Corbin and Rannels, 1981; Taylor and Uhler, 2000; Weber et al., 1987; 
Woodford et al., 1989). These structural differences between PKA I and PKG I as well as 
PKG I and PKG II suggest different mechanisms of activation by cyclic nucleotides.  
A number of approaches have been implemented to better understand the 
molecular events associated with activation of PKG I. Previous studies using 
hydrodynamic and small-angle x-ray scattering techniques have demonstrated that cGMP 
binding to the regulatory domain of PKG Iα and β induces substantial conformational 
changes (Richie-Jannetta et al., 2006; Wall et al., 2003; Zhao et al., 1997). However, the 
individual contributions of each cGMP-binding site still remain unknown. Our attempt to 
address this question is based on mutational studies in PKA that led to the development 
of a sequential model of type I α PKA activation (Herberg et al., 1996). Previous reports 
have identified six highly conserved aminoacids (Gly199, Glu200, Arg209, Gly323, 
Glu324 and Arg333) in the regulatory subunit of PKA I α that were critical for cAMP 
binding (Bubis et al., 1988; Neitzel et al., 1991; Ogreid et al., 1988; Steinberg et al., 
1991; Steinberg et al., 1987). It has since been confirmed by X-ray crystallography that 
the highly conserved glutamate, glycine and arginine indeed coordinate cAMP in the 
regulatory subunit to the 2’-OH of the ribose and to the cyclic phosphate moiety, 
respectively (Diller et al., 2001; Su et al., 1995; Zawadzki and Taylor, 2004). 
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To gain more insight into the actual cGMP binding mechanism in PKG I α and 
the molecular mechanism of kinase activation, we have introduced single point mutations 
(G167E, E168G, R177K, G291E, E292G and R301K) and have analyzed their kinetic 
characteristics with respect to kinase activity depending on cGMP and substrate, as well 
as for cGMP binding and dissociation. These mutants allowed us to gain insight into: (1) 
the specific sites of communication between regulatory and catalytic domains of PKG, 
(2) conformational changes associated with cGMP binding, (3) greatly expand our 
current knowledge about the molecular mechanism of PKG activation and also allude to 
(4) fundamental differences in the molecular mechanism of activation between PKG I α 
and PKA I α. 
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Results: 
Allosteric binding site mutants of PKG I α 
Aminoacid-sequence alignment of cyclic nucleotide binding sites A and B 
revealed two highly conserved regions, FGE…RTA for PKG I α and FGE…RAA for 
PKA I α respectively (Figure 1A) (Francis and Corbin, 1994; Weber et al., 1989). Both 
sequence motifs flank the cyclic-phosphate binding cassette critical for the riboside 
moiety and phosphate-diester recognition (Berman et al., 2005; Diller et al., 2001; Wu et 
al., 2004). The charged residues as well as the glycine residue in each binding cassette of 
PKA I α were of special interest since alterations of these amino acids led to a complete 
loss of cyclic nucleotide binding to that site (Gorman and Steinberg, 1994; Murphy and 
Steinberg, 1985; Ogreid et al., 1988; Steinberg et al., 1991; Steinberg et al., 1987). 
Further studies have demonstrated that the loss-of-function glycine, glutamate and 
arginine mutations in the regulatory subunits RIα and RIIβ were particularly useful to aid 
our understanding of the mechanism of PKA activation (Bubis et al., 1988; Dostmann 
and Taylor, 1991; Neitzel et al., 1991; Wu et al., 2004; Zawadzki and Taylor, 2004). The 
goal of this study was to determine if the glycine, glutamate or arginine residues present 
in each of the PKG I α binding site pockets modulate (1) cGMP binding to site A and/or 
B of the PKG regulatory domain and (2) cGMP specific activation of the kinase catalytic 
domain (Figure 1 B). Therefore in analogy to PKA, we selected the following PKG I α 
mutants: G167E, E168G, R177K, G291E, E292G and R301K (Figure 1 A). To assess 
their kinetic characteristics, all PKG I α mutant and wildtype proteins were expressed in 
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SF9-cells and purified to apparent homogeneity using cAMP-affinity chromatography 
(Figure 1 C; see Methods).  
 
Stoichiometry of PKG I α cGMP-binding site mutants 
First, we conducted binding studies using [3H]-labeled cGMP (Doskeland and 
Ogreid, 1988; Dostmann et al., 1996; Ogreid and Doskeland, 1981) to determine the 
influence of the point mutations on the overall cGMP binding capacity (Figure 1 D; Table 
1). Replacement of either glycine or glutamate residues in site A (G167E, E168G) or site 
B (G291E, E292G) was sufficient to reduce the stoichiometry of cGMP binding to one 
ligand per PKG regulatory domain. In contrast to the type Iα regulatory subunit of PKA, 
the arginine to lysine mutants (R177K and R301K) fully retained cGMP binding to both 
sites A and B (Figure 1 D and Table 1).  
To verify the reduced cGMP binding capacity in the glutamate to glycine mutants 
(E168G, E292G), we utilized electrospray ionization mass spectrometry (ESI) under non-
denaturing conditions (Figures 2 A-F). In agreement with previously published reports, 
PKG wildtype gave rise to intense charge state distribution ranging from 23+ to 29+ and 
yielding a mass charge envelope of 5,000 to 6,500 m/z (Pinkse et al., 2004; Scholten et 
al., 2007) (Figure 2 A). Deconvolution spectra indicate that dimeric native PKG bound in 
average two molecules cyclic nucleotides (Figure 2 A, inset), and possibly residual 
cAMP from eluting the protein from affinity column or cyclic nucleotides endogenously 
present in SF9 cells. Incubation of wildtype PKG with cGMP (20 µM) predicts binding 
of four cGMP molecules per dimeric wildtype PKG (measured mass 154.3 kDa) in 
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accordance to the number of expected nucleotide binding sites in the dimeric kinase PKG 
(Figure 2 B). Both PKG mutants E168G and E292G co-eluted with other (unidentified) 
proteins from the affinity columns, however, both PKG mutants gave rise to charge state 
distributions of sufficient intensities and qualities to observe and analyze distinct PKG 
species (Figures 2 C to F). Deconvolution of the complex charge state distribution of 
PKG E292G indicated the presence of dimeric PKG E292G with no cyclic nucleotide, 
one and two cyclic nucleotides with approximate contributions of 20%, 38% and 42%, 
respectively, as estimated from the deconvoluted mass spectrum (Figure 2 C, inset). 
Incubation with 20 µM cGMP gave rise to a stoichiometry of two cGMP molecules per 
dimeric PKG E292G (with a measured mass of 153.6 kDa) (Figure 2 D).  A minor 
fraction (< 20%) of E292G dimer containing three cGMP (measured mass 153.9 kDa) 
was also observed. Similarly, nano-electrospray mass spectrometry revealed dimeric 
PKG E168G bound to one or two residual cyclic nucleotides (15 and 85 % contribution, 
respectively), (Figure 2 E). After incubation with 20 µM cGMP, the predominating 
species observed were again dimeric E168G bound to two or three cyclic nucleotides 
(with contribution of 80-85 % and 15-20 %, respectively), (Figure 2 F). Therefore, ESI 
mass spectrometry supports the [3H]-cGMP binding assays suggesting loss of cGMP 
binding in the mutated cGMP binding sites (E168G, E292G). 
 
Kinetic characterization of site A loss-of-function mutants of PKG I α 
To gain insight into specific cGMP binding sites of PKG I α, all identified single 
site binding mutants (G167E, E168G, G291E, E292G) were tested for their cGMP 
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binding, dissociation and activation kinetics. First, we studied the kinetic behavior of the 
N-terminal binding site A mutants G167E and E168G (Figure 3). In contrast to PKG 
wildtype (KD = 40 nM), both PKG mutants displayed increased cGMP binding constants 
(KD) of 385 nM and 195 nM for G167E and E168G, respectively (Figure 3 A; Table 1). 
Skatchard analysis confirmed binding of a single cGMP molecule to the functional, low 
affinity site B (KD = 327 nM and 197 nM for G167E and E168G, respectively; Table 1; 
Figure 3 B). Based on their Hill coefficients, G167E (nH = 0.6) and E168G (nH = 0.8) 
exhibited non-cooperative cGMP binding behavior, further indicating the presence of a 
single cGMP binding site in both mutants. In contrast, PKG wildtype displayed highly 
cooperative cGMP binding (nH = 1.5), indicating positive cooperativity and cross-talk 
between sites A and B under native conditions, as reported previously (Wolfe et al., 
1989). In agreement with cGMP binding studies, cGMP dissociation kinetics attested 
monophasic, fast dissociation from the isolated, cGMP binding site B in G167E and 
E168G (k-1 = 11.8 and 22.2 min-1, respectively; Table 2; Figures 3 D, E). Dissociation as 
well as binding assays confirmed impaired cGMP binding to site A, and intact cGMP 
binding to site B, thereby identifying site A as high affinity, and site B as low affinity 
binding sites in PKG I α. Surprisingly, kinase activation of mutants G167E and E168G 
did not reveal higher activation constants Ka, indicative of lower cGMP binding affinity 
(Figure 3 F, Table 3). Instead, site A knock-out mutants exhibited basal, cGMP-
independent catalytic activity (10 to 20 %; Figure 3 F) but could not be fully activated in 
presence of increasing cGMP concentrations. Therefore, glycine 167 and glutamate 168 
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are not only critical for cGMP binding to site A but also reveal that cGMP binding to a 
functional cGMP binding site A is essential for kinase activation (Figure 3 G). 
 
Kinetic characterization of site B loss-of-function mutants of PKG I α 
Next, we investigated cGMP binding, dissociation and kinase activity of the C-
terminal, low affinity binding site B mutants G291E and E292G (Figure 4). Replacement 
of glycine 291 or glutamate 292 led to monophasic, non-cooperative cGMP binding with 
slightly lower KD-values of 26 nM and 18 nM for G291E and E292G, respectively, 
compared to PKG wildtype (Table 1; Figure 4 A). Skatchard analysis confirmed binding 
of a single cGMP molecule to the functional high affinity site A (KD = 29 nM and 21 nM 
for G291E and E292G, respectively; Table 1; Figure 4 B). Similar to site A knock-out 
mutants, Hill coefficients for G291E (nH = 0.9) and E292G (nH = 0.9) indicated non-
cooperative cGMP binding (Figure 4 C). In addition, cGMP dissociation kinetics verified 
slow, monophasic dissociation from site A for mutants G291E (k-1 = 0.01 min-1; τ1/2 = 80 
min) and E292G (k-1 = 0.01 min-1; τ1/2 = 90 min) (Table 2; Figures 4 D, E). In agreement 
with site A knock-out mutants (Figure 3), dissociation and association kinetics of site B 
knock-out mutants confirm that site A and B are high- and low- affinity binding sites for 
cGMP, respectively. In contrast to site A knock-out mutants, site B mutants clearly 
demonstrated cGMP-dependent activation (Figure 4 F) with maximal kinase activity 
comparable to wildtype PKG. However, apparent activation constants (Ka) revealed that 
mutants G291E (Ka = 18 nM) and E292G (Ka = 37 nM) bound cGMP with an even 
higher affinity than wildtype (Ka = 53 nM), reflecting cGMP binding and kinase 
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activation through the higher affinity, intact site A (Figure 4 G, Table 3). Hence, glycine 
291 and glutamate 292 are critical for cGMP binding to site B (Figure 4 G), but cGMP 
binding to site B is not essential for PKG activation. In the absence of cooperativity, 
cGMP binding to a functional site A is sufficient and promotes full PKG activation.  
 To further investigate the cross-talk between regulatory and catalytic domains of 
PKG I α, we tested the PKG mutants E168G and E292G for maximal catalytic activity 
depending on substrate concentration and for Michaelis-Menten constants (KM) in 
comparison to PKG wildtype catalytic activity (Figure 5, Table 3). When probing E168G 
for catalytic activity depending on substrate concentration, this mutant showed an overall 
decreased reaction velocity (vmax = 3 ± 0.2 µmol/(mg x min)) and KM value (310 ± 5 nM) 
as compared to wildtype (KM = 705 ± 20 nM) (Table 3). In contrast, impaired cGMP 
binding to site B had no influence on catalytic velocity, since E292G showed KM (968 ± 
26 nM) and vmax values (vmax = 8.9 ± 0.3 µmol/(mg x min)) similar to wildtype PKG I α 
(vmax = 10.5 ± 0.4 µmol/(mg x min)). These findings further support our hypothesis that a 
dysfunctional site A directly impacts kinase fidelity, thus a fully functional cGMP-
binding site A appears to be vital for full PKG activity and seemingly independent of the 
cGMP binding site B. 
 
Kinetic characterization of R301K and R177K mutants of PKG I α 
Next, we studied the kinetic behavior of PKG mutants R177K and R301K (Figure 
6). In contrast to previous studies utilizing PKA (Bubis et al., 1988; Zawadzki and 
Taylor, 2004), both arginine to lysine mutants fully retained cGMP binding to both sites 
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A and B (Figures 2 A, 6 A). Despite full cGMP binding capacity, R177K and R301K 
displayed slightly shifted cGMP activation (Figure 6 A) and binding constants (Figure 6 
B) towards higher (R301K) and lower (R177K) cGMP affinity as compared to PKG 
wildtype (Tables 1 and 3). This suggests that the arginine to lysine mutations modulate, 
but not diminish, cGMP binding to the mutated cGMP binding site. Hill analysis revealed 
diminished cGMP-cooperativity (nH = 1.1) as compared to PKG wildtype (nH = 1.5), 
indicating that the communication between sites A and B is impaired (Figure 6 C; Table 
1). In agreement with kinase activation and cGMP binding studies, cGMP dissociation 
kinetics attested biphasic dissociation for both mutants (Figures 6 D; Table 2). 
Dissociation kinetics were faster as compared to wildtype and might be a reflection of 
reduced cooperativity between cGMP binding sites A and B. These results suggest that 
both sites A and B need to be functional and cooperative, in order to achieve cGMP 
binding and kinase activation as seen under native, wildtype conditions. 
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Discussion: 
In the past, extensive mutational analysis has helped to identify six highly 
conserved aminoacids (Gly199, Glu200, Arg209, Gly323, Glu324 and Arg333) in the 
regulatory subunit of PKA I α that were critical for cAMP binding (Bubis et al., 1988; 
Ogreid et al., 1988; Steinberg et al., 1991; Steinberg et al., 1987). It has since been 
confirmed by X-ray crystallography that the highly conserved glutamate, glycine, 
arginine indeed coordinate cAMP in the regulatory subunit with hydrogen bonds (Su et 
al., 1995; Zawadzki and Taylor, 2004). In PKA I α, glutamate 200 has been shown to 
coordinate the ribosyl-hydroxy-group of cAMP in the regulatory subunit. Furthermore, 
arginine 209 has been identified to stabilize cAMP by interacting with the negatively 
charged, axial oxygen of the cAMP-phosphate group (Dostmann and Taylor, 1991; 
Dostmann et al., 1990; Su et al., 1995). In our studies, however, only the homologous 
glutamate (E168, E292), but not the arginine (R177, R301), was crucial for cGMP 
binding to the regulatory domain of PKG I α. Both site A and B knock-out mutants 
(E168G, E292G) in PKG I α confirm that the highly conserved glutamate is essential for 
cGMP binding. Replacement of glycine (G167, G291) with glutamate might interfere 
with cGMP binding due to charge-repulsion caused by the sterically large, charged 
glutamate, and therefore, conclusions about glycine-cGMP interactions cannot be drawn. 
In this study, abolishing cGMP binding to site A or site B has proven to be an invaluable 
tool to gain insight into the molecular mechanism of PKG activation.  
For site A knock out mutants, cGMP binding to lower affinity site B is still 
functional but not sufficient to fully activate PKG I α (Figures 3 and 7 A). This suggests 
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that coupling between a functional site A and the catalytic domain (A-C coupling) is 
necessary to fully activate PKG. Site B knock-out mutations further support the 
hypothesis, that the catalytic domain is activated directly through site A (Figure 4 and 7 
B). In absence of a functional site B, cGMP binding to site A leads to A-C coupling and 
to full PKG activation. Besides A-C coupling, the interactions between cGMP binding 
sites A and B also play a crucial part in PKG activation. Loss of binding to either one of 
the cGMP binding sites consequentially results in loss of cooperativity, as shown by Hill 
analysis (Table 1). Due to lack of cooperativity, activation and binding curves for site B 
knock-out mutants are shifted towards higher affinities, reflecting the influence of only 
one cGMP site, the high affinity site A. The modulatory influence of site B on site A is 
lost, and therefore, activation and binding constants are very similar and shifted towards 
higher affinities for site B knock-out mutants (e.g. for E291G: Ka = 18 nM; KD = 26 nM) 
(Tables 1 and 3). In contrast, the activation constant (Ka = 53 nM) for PKG wildtype 
represents a combination of binding constants for both sites A and B and is significantly 
higher than the binding constant for PKG wildtype site A (KD = 6/110 nM for site A/B; 
Table 1; (Hofmann et al., 1985)), indicating the modulatory effect of site B on site A. The 
un-coupling of both cGMP binding sites G291E and E292G allows kinase activation 
through site A, since the modulatory (negative) influence of site B on site A is lost.  
Based on these results, we present the following mechanism of activation for 
PKG wildtype (Figure 7 C): both cGMP binding sites A and B are equally accessible to 
bind cGMP. At low cGMP concentrations, site A is fully occupied (KD = 6 nM; Table 1), 
but site B (KD = 110 nM; Table 1) prevents site A from activating the catalytic domain 
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(A-C coupling interrupted) due to cooperative, (negative-) modulatory effects (nH = 1.5; 
Table 1). Only when both sites A and B are fully occupied with cGMP, site A can 
communicate to the catalytic domain and initiate the release of the autoinhibitory domain, 
hence making the catalytic domain accessible for substrates (Figure 7 C).  
Several conclusions can be drawn from the proposed concerted mechanism of 
PKG activation: this activation mechanism reveals that site B plays a pivotal role in 
modulating responsiveness of PKG to a broader range of [cGMP]i. Therefore, the 
mechanism for PKG activation might have developed during evolution in order to allow 
PKG to react in response to raising [cGMP]i levels and not to basal cGMP levels in cells 
(Francis et al., 1988; Kotera et al., 2003). In addition, the concerted mechanism of 
activation for PKG is significantly different from the sequential mechanism of PKA 
activation. Biochemical data as well as the recently published crystal structure of PKA 
holoenzyme propose a highly ordered and sequential pathway of cAMP binding to the 
type I α PKA holoenzyme in which domain B serves as a ‘‘gatekeeper’’ for cAMP access 
to domain A (Herberg et al., 1996; Kim et al., 2007; Kim et al., 2005). 
Besides being very useful tools to decipher the mechanism of PKG activation, site 
A and B knock-out mutants also determine for the first time the distinct structural order 
of fast and slow cyclic nucleotide binding sites relative to the NH2 terminus in PKG I α. 
For PKG I β, the slow nucleotide dissociation site is closer to the NH2 terminus than the 
fast dissociation site (Reed, RB, Corbin JD JBC 1996), whereas for PKA I and PKG II, 
the fast dissociation site is closer to the NH2 terminus (Bubis and Taylor, 1987; Corbin 
and Rannels, 1981; Taylor and Uhler, 2000; Weber et al., 1987; Woodford et al., 1989). 
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Similar to PKG I β, the slow nucleotide dissociation site is closer to the NH2 terminus 
than the fast dissociation site for PKG I α.  
In conclusion, our data suggest an overall concerted mechanism of activation for 
PKG I α that is significantly different from the sequential mechanism of PKA activation 
(Kim et al., 2007; Kim et al., 2005). Our results support coupling between both cGMP 
binding sites A and B, as well as coupling between cGMP binding site A and the catalytic 
domain. Furthermore, the structural order of high and low affinity binding sites for PKG I 
α is similar to PKG I β, since the high affinity binding site A is closer to the NH2 
terminus. Structural insights into PKG would greatly advance our understanding of 
cGMP coordination in the regulatory domain and the complexity involved in kinase 
activation. 
 53
Methods 
Mutagenesis, expression and purification 
cGMP-binding mutants were constructed by introducing single site specific mutations in 
the regulatory domain of bovine PKG I α at positions G167E, E168G, R177K, G291E, 
E292G and R301K. PKG constructs were preceded by a BamHI site and a start codon 
(ATG), and followed by a stop codon and an EcoRI site. The entire PKG coding 
sequences were inserted into the BamHI and EcoRI sites of pFAST-BAC vector 
(invitrogen) and transected into SF9 cells for expression. 
PKG wildtype and mutants were expressed in SF9 cells using the Bac-to-Bac system and 
purified utilizing cyclic nucleotide affinity chromatography as described previously (Feil 
et al., 1993). 
 
Kinase activity 
KM and vmax values were determined according to Ruth and colleagues (Ruth et al., 1991) 
by measuring the kinase activity for 1.5 min at 30°C in a final volume of 100 µl 
containing 20 µl buffer (250 mM MES pH 6.9; 2 mM EGTA; 5 mM Mg-Acetate; 50 mM 
NaCl), 10 µl BSA (10 mg/ml); 10 µl DTT (100 mM); 10 µl [γ-32P] ATP (1 mM; specific 
activity 300-400 cpm/pmol), 10 µl cGMP (1 mM) or water, 10 µl appropriate peptide 
solution, and 20 µl PKG (5 mM MES, pH 7.0; 0.2 mM EDTA; 0.5 mg/ml BSA) to a final 
concentration of 2.6 nM. Fifty five-microliter aliquots were spotted on 2 x 2 cm phospho-
cellulose paper strips (P-81 Whatman), extensively washed in 75 mM phosphoric acid, 
and the dried strips were subjected to scintillation counting. Peptide 
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(TQAKRKKSLAMA, (Dostmann et al., 2000)) concentrations ranged from 125 nM to 
saturating levels, and all assays were run in duplicate. Similar procedures were used to 
determine the Ka values. Ten-microliter aliquots of peptide (200 µM) were added to each 
assay, and the cGMP concentrations varied from 1 nM to saturating levels.  
 
cGMP binding and dissociation 
cGMP binding was assayed by incubating PKG enzyme (25 nM) for 90 minutes at 4°C 
with various concentrations of [3H]-GMP, before precipitating and filtering as described 
previously (Dostmann et al., 1996; Ruth et al., 1991). Similar procedures were used to 
follow cGMP dissociation. Proteins were incubated at 4°C for 90 min in the presence of 
250 nM [3H]-cGMP and dissociation was initiated by the addition of 10 µM cold cGMP. 
Hill analysis was performed to determine Hill coefficients (nH) with the log[b/(bmax-b)] 
plotted against the log of the cyclic nucleotide concentration [M], where b indicates 
fractional cGMP binding. Skatchard analysis was used to determine single binding site 
affinities by plotting [cGMP (bound/free)] against bound cGMP. 
 
Electrospray ionization mass spectrometry (ESI) 
Mass spectra of intact protein or cGMP-protein complexes were recorded on a time-of-
flight (TOF) mass spectrometer (Micromass LCT classic model, Waters, Manchester, 
UK), fitted with a nano-electrospray source (Waters, Manchester, UK). Samples were 
introduced by means of Au/Pd coated borosilicate capillaries (Cat. No. ES380, Proxeon 
Biosystems, Odense, Denmark). Data were recorded in the positive ion mode between 
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m/z 3000 - 8000 under conditions of increased pressure in the source and intermediate 
pressure regions measured by built-in gauges in the mass spectrometer (Pirani gauge 7 
mBar and Penning gauge 9 x 10-7 mBar) (Pinkse et al., 2004; Tahallah et al., 2001) and 
processed using the MassLynx 4.0 software (Waters, Manchester, UK). Nanoflow 
electrospray voltages were optimized for transmission of larger multimer protein 
assemblies (capillary voltage 1800 -1900 V and cone voltage 120-140 V). For sample 
preparation, PKG was buffer exchanged to a volatile buffer containing 200 mM 
ammonium acetate (pH 6.7) with Ultrafree-0.4 centrifugal filter units (5000 NMWL, 
Millipore, Bedford, MA, USA) and concentrated to 5 µM final. cGMP (20 µM final 
concentration), when applied, was also dissolved in this buffer and preincubated with 
PKG on ice for 5 min before analysis by ESI.  
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Table 1: cGMP binding kinetics and stoichiometry of PKG mutants and wildtype 
PKG N1 KD2 [nM] KD3 [nM] nH4
   Site A Site B  
WT 1.6 ± 0.2 40 6 110 1.5 
G167E 0.8 ± 0.1 382 - 327 0.6 
E168G 0.6 ± 0.05 195 - 197 0.8 
G291E 0.8 ± 0.1 26 29 - 0.9 
E292G 0.7 ± 0.1 18 21 - 0.9 
R177K 1.5 ± 0.2 172 - - 1.1 
R301K 1.7 ± 0.2 12 - - 1.1 
1 N = Stoichiometry; 2: from [3H]-cGMP binding assays; 3: from Skatchard analysis;  
4 Hill coefficient; the values represent the mean ± SEM of 6 to 9 experiments. 
 
 
Table 2: Dissociation kinetics of PKG mutants and wildtype 
PKG k-1 [min-1] τ1/2 [min] 
 Site A Site B Site A Site B 
WT 0.01 ± 0.005 5.5 ± 0.3 110 0.18 
G167E - 11.8 ± 0.1 - 0.09 
E168G - 22.2 ± 0.1 - 0.05 
G291E 0.01 ± 0.003 - 80 - 
E292G 0.01 ± 0.001 - 90 - 
R177K 0.02 ± 0.003 6.7 ± 0.2. 55 0.15 
R301K 0.07 ± 0.002 8.5 ± 0.2 15 0.12 
The values represent the mean ± SEM of 6 to 9 experiments. 
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Table 3: Catalytic activity of PKG mutants and wildtype 
PKG   Activation Substrate turn-over
 Ka [nM] vmax [µmol x mg-1 x min-1] KM [nM] vmax [µmol x mg-1 x min-1] 
WT 53 ± 4 9.7 ± 0.2 705 ± 20 10.5 ± 1.3 
G167E - 1.6 ± 0.3 150 ± 4 2.9 ± 0.3 
E168G - 2.7 ± 0.1 310 ± 5 3.0 ± 0.3 
G291E 18 ± 3 10.4 ± 0.2 654 ± 21 9.7 ± 1.0 
E292G 37 ± 5 10.2 ± 0.4 968 ± 26 8.9 ± 0.3 
R177K 620 ± 10 12.1 ± 0.1 653 ± 15 11.6 ± 0.2 
R301K 16 ± 2 11.7 ± 0.5 890 ± 33 11.1 ± 0.5 
The values represent the mean ± SEM of 6 to 9 experiments. 
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Figure legends 
Figure 1: (A) Sequence alignment of PKG I α and PKA I α cyclic nucleotide binding 
sites; asterixes denote identical amino-acids, and residues targeted for site specific 
mutagenesis for this study are indicated with arrows. (B) Domain composition of PKG I 
α. (C) 10% SDS-PAGE of PKG I α wildtype (WT) and all affinity-purified mutants (1-5 
µg protein per lane). (D) Stoichiometry of wild type and single-site cyclic nucleotide 
binding mutants using [3H]-cGMP binding assays (see Methods). 
 
Figure 2: Native electrospray ionization mass spectra of PKG wildtype (A, B) and 
mutants E292G (C, D) and E168G (E, F) in the absence (left) and presence (right) of 20 
µM cGMP. The mass spectra indicate distribution of charge state, the corresponding 
insets show the respective de-convoluted mass spectra. Peaks marked with asterixes 
indicate unidentified proteins. 
 
Figure 3: Kinetic characterization of PKG mutants G167E (∆) and E168G ( ) in 
comparison to PKG wildtype ( ). (A) [3H]-cGMP binding studies with (B) Skatchard and 
(C) Hill analysis. (D, E) [3H]-cGMP dissociation from (D) slow and (E) fast cGMP 
binding sites A and B, respectively. (F) cGMP dependent kinase activation of (G) PKG 
site A mutants.  
 
Figure 4: Kinetic characterization of PKG mutants G291E ( ) and E292G ( ) in 
comparison to PKG wildtype ( ). (A) [3H]-cGMP binding studies with (B) Skatchard and 
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(C) Hill analysis. (D, E) [3H]-cGMP dissociation from (D) slow and (E) fast cGMP 
binding sites A and B, respectively. (F) cGMP dependent kinase activation of (G) PKG 
site B mutants. 
 
Figure 5: Substrate (LAMA, see Methods)-dependent kinase activity of PKG wildtype   
( ), E168G ( ) and E292G ( ). 
 
Figure 6: Kinetic characterization of PKG mutants R177K (x) and R301K ( )) in 
comparison to PKG wildtype ( ). (A) cGMP dependent kinase activation (B) [3H]-cGMP 
binding studies with (C) Hill analysis. (D) [3H]-cGMP dissociation from (D) slow and 
fast sites A and B, respectively.  
 
Figure 7: Model for activation of (A) site A knock-out mutants, (B) site B knock-out 
mutants and (C) PKG wildtype.  
 60
Figure 1: 
 
 
 
 61
Figure 2: 
 
 62
Figure 3: 
 
 
 
 63
Figure 4: 
 
 
 
 64
Figure 5: 
 
 
 
 65
Figure 6: 
 
 
 
 
 66
Figure 7: 
 
 
 
 
 
 67
References: 
 
Berman HM, Ten Eyck LF, Goodsell DS, Haste NM, Kornev A and Taylor SS. The 
cAMP binding domain: an ancient signaling module. Proc Natl Acad Sci U S A 102(1): 
45-50, 2005. 
 
Brostrom CO, Corbin JD, King CA and Krebs EG. Interaction of the subunits of 
adenosine 3':5'-cyclic monophosphate-dependent protein kinase of muscle. Proc Natl 
Acad Sci U S A 68(10): 2444-7, 1971. 
 
Bubis J, Neitzel JJ, Saraswat LD and Taylor SS. A point mutation abolishes binding 
of cAMP to site A in the regulatory subunit of cAMP-dependent protein kinase. J Biol 
Chem 263(20): 9668-73, 1988. 
 
Bubis J and Taylor SS. Correlation of photolabeling with occupancy of cAMP binding 
sites in the regulatory subunit of cAMP-dependent protein kinase I. Biochemistry 26(12): 
3478-86, 1987. 
 
Corbin JD and Rannels SR. Perturbation and structural organization of the two 
intrachain cAMP binding sites of cAMP-dependent protein kinase II. J Biol Chem 
256(22): 11671-6, 1981. 
 
Diller TC, Madhusudan, Xuong NH and Taylor SS. Molecular basis for regulatory 
subunit diversity in cAMP-dependent protein kinase: crystal structure of the type II beta 
regulatory subunit. Structure 9(1): 73-82, 2001. 
 
Doskeland SO and Ogreid D. Ammonium sulfate precipitation assay for the study of 
cyclic nucleotide binding to proteins. Methods Enzymol 159: 147-50, 1988. 
 
Doskeland SO, Vintermyr OK, Corbin JD and Ogreid D. Studies on the interactions 
between the cyclic nucleotide-binding sites of cGMP-dependent protein kinase. J Biol 
Chem 262(8): 3534-40, 1987. 
 
Dostmann WR, Koep N and Endres R. The catalytic domain of the cGMP-dependent 
protein kinase Ialpha modulates the cGMP-binding characteristics of its regulatory 
domain. FEBS Lett 398(2-3): 206-10, 1996. 
 
Dostmann WR, Taylor MS, Nickl CK, Brayden JE, Frank R and Tegge WJ. Highly 
specific, membrane-permeant peptide blockers of cGMP-dependent protein kinase Ialpha 
inhibit NO-induced cerebral dilation. Proc Natl Acad Sci U S A 97(26): 14772-7, 2000. 
 
Dostmann WR and Taylor SS. Identifying the molecular switches that determine 
whether (Rp)-cAMPS functions as an antagonist or an agonist in the activation of cAMP-
dependent protein kinase I. Biochemistry 30(35): 8710-6, 1991. 
 68
 
Dostmann WR, Taylor SS, Genieser HG, Jastorff B, Doskeland SO and Ogreid D. 
Probing the cyclic nucleotide binding sites of cAMP-dependent protein kinases I and II 
with analogs of adenosine 3',5'-cyclic phosphorothioates. J Biol Chem 265(18): 10484-
91, 1990. 
 
Erlichman J, Rubin CS and Rosen OM. Physical properties of a purified cyclic 
adenosine 3':5'-monophosphate-dependent protein kinase from bovine heart muscle. J 
Biol Chem 248(21): 7607-9, 1973. 
 
Feil R, Muller S and Hofmann F. High-level expression of functional cGMP-dependent 
protein kinase using the baculovirus system. FEBS Lett 336(1): 163-7, 1993. 
 
Francis SH and Corbin JD. Structure and function of cyclic nucleotide-dependent 
protein kinases. Annu Rev Physiol 56: 237-72, 1994. 
 
Francis SH, Noblett BD, Todd BW, Wells JN and Corbin JD. Relaxation of vascular 
and tracheal smooth muscle by cyclic nucleotide analogs that preferentially activate 
purified cGMP-dependent protein kinase. Mol Pharmacol 34(4): 506-17, 1988. 
 
Gill GN and Garren LD. Role of the receptor in the mechanism of action of adenosine 
3':5'-cyclic monophosphate. Proc Natl Acad Sci U S A 68(4): 786-90, 1971. 
 
Gill GN, Holdy KE, Walton GM and Kanstein CB. Purification and characterization 
of 3':5'-cyclic GMP-dependent protein kinase. Proc Natl Acad Sci U S A 73(11): 3918-22, 
1976. 
 
Gorman KB and Steinberg RA. Spectrum of spontaneous missense mutations causing 
cyclic AMP-resistance phenotypes in cultured S49 mouse lymphoma cells differs 
markedly from those of mutations induced by alkylating mutagens. Somat Cell Mol 
Genet 20(4): 301-11, 1994. 
 
Herberg FW, Taylor SS and Dostmann WR. Active site mutations define the pathway 
for the cooperative activation of cAMP-dependent protein kinase. Biochemistry 35(9): 
2934-42, 1996. 
 
Hofmann F, Gensheimer HP and Gobel C. cGMP-dependent protein kinase. 
Autophosphorylation changes the characteristics of binding site 1. Eur J Biochem 147(2): 
361-5, 1985. 
 
Kemp BE, Bylund DB, Huang TS and Krebs EG. Substrate specificity of the cyclic 
AMP-dependent protein kinase. Proc Natl Acad Sci U S A 72(9): 3448-52, 1975. 
 
 69
Kim C, Cheng CY, Saldanha SA and Taylor SS. PKA-I holoenzyme structure reveals 
a mechanism for cAMP-dependent activation. Cell 130(6): 1032-43, 2007. 
 
Kim C, Xuong NH and Taylor SS. Crystal structure of a complex between the catalytic 
and regulatory (RIalpha) subunits of PKA. Science 307(5710): 690-6, 2005. 
 
Kotera J, Grimes KA, Corbin JD and Francis SH. cGMP-dependent protein kinase 
protects cGMP from hydrolysis by phosphodiesterase-5. Biochem J 372(Pt 2): 419-26, 
2003. 
 
Lincoln TM, Dills WL, Jr. and Corbin JD. Purification and subunit composition of 
guanosine 3':5'-monophosphate-dependent protein kinase from bovine lung. J Biol Chem 
252(12): 4269-75, 1977. 
 
Monken CE and Gill GN. Structural analysis of cGMP-dependent protein kinase using 
limited proteolysis. J Biol Chem 255(15): 7067-70, 1980. 
 
Murphy CS and Steinberg RA. Hotspots for spontaneous and mutagen-induced lesions 
in regulatory subunit of cyclic AMP-dependent protein kinase in S49 mouse lymphoma 
cells. Somat Cell Mol Genet 11(6): 605-15, 1985. 
 
Neitzel JJ, Dostmann WR and Taylor SS. Role of MgATP in the activation and 
reassociation of cAMP-dependent protein kinase I: consequences of replacing the 
essential arginine in cAMP binding site A. Biochemistry 30(3): 733-9, 1991. 
 
Ogreid D and Doskeland SO. Protein kinase II has two distinct binding sites for cyclic 
AMP, only one of which is detectable by the conventional membrane-filtration method. 
FEBS Lett 121(2): 340-4, 1980. 
 
Ogreid D and Doskeland SO. The kinetics of association of cyclic AMP to the two 
types of binding sites associated with protein kinase II from bovine myocardium. FEBS 
Lett 129(2): 287-92, 1981. 
 
Ogreid D, Doskeland SO, Gorman KB and Steinberg RA. Mutations that prevent 
cyclic nucleotide binding to binding sites A or B of type I cyclic AMP-dependent protein 
kinase. J Biol Chem 263(33): 17397-404, 1988. 
 
Ogreid D, Doskeland SO and Miller JP. Evidence that cyclic nucleotides activating 
rabbit muscle protein kinase I interact with both types of cAMP binding sites associated 
with the enzyme. J Biol Chem 258(2): 1041-9, 1983. 
 
Pfeifer A, Ruth P, Dostmann W, Sausbier M, Klatt P and Hofmann F. Structure and 
function of cGMP-dependent protein kinases. Rev Physiol Biochem Pharmacol 135: 105-
49, 1999. 
 70
 
Pinkse MW, Heck AJ, Rumpel K and Pullen F. Probing noncovalent protein-ligand 
interactions of the cGMP-dependent protein kinase using electrospray ionization time of 
flight mass spectrometry. J Am Soc Mass Spectrom 15(10): 1392-9, 2004. 
 
Reed RB, Sandberg M, Jahnsen T, Lohmann SM, Francis SH and Corbin JD. Fast 
and slow cyclic nucleotide-dissociation sites in cAMP-dependent protein kinase are 
transposed in type Ibeta cGMP-dependent protein kinase. J Biol Chem 271(29): 17570-5, 
1996. 
 
Reimann EM, Brostrom CO, Corbin JD, King CA and Krebs EG. Separation of 
regulatory and catalytic subunits of the cyclic 3',5'-adenosine monophosphate-dependent 
protein kinase(s) of rabbit skeletal muscle. Biochem Biophys Res Commun 42(2): 187-94, 
1971. 
 
Richie-Jannetta R, Busch JL, Higgins KA, Corbin JD and Francis SH. Isolated 
regulatory domains of cGMP-dependent protein kinase Ialpha and Ibeta retain 
dimerization and native cGMP-binding properties and undergo isoform-specific 
conformational changes. J Biol Chem 281(11): 6977-84, 2006. 
 
Ruth P, Landgraf W, Keilbach A, May B, Egleme C and Hofmann F. The activation 
of expressed cGMP-dependent protein kinase isozymes I alpha and I beta is determined 
by the different amino-termini. Eur J Biochem 202(3): 1339-44, 1991. 
 
Scholten A, Fuss H, Heck AJ and Dostmann WR. The hinge region operates as a 
stability switch in cGMP-dependent protein kinase I alpha. Febs J 274(9): 2274-86, 2007. 
 
Scott JD. Cyclic nucleotide-dependent protein kinases. Pharmacol Ther 50(1): 123-45, 
1991. 
 
Steinberg RA, Gorman KB, Ogreid D, Doskeland SO and Weber IT. Mutations that 
alter the charge of type I regulatory subunit and modify activation properties of cyclic 
AMP-dependent protein kinase from S49 mouse lymphoma cells. J Biol Chem 266(6): 
3547-53, 1991. 
 
Steinberg RA, Russell JL, Murphy CS and Yphantis DA. Activation of type I cyclic 
AMP-dependent protein kinases with defective cyclic AMP-binding sites. J Biol Chem 
262(6): 2664-71, 1987. 
 
Su Y, Dostmann WR, Herberg FW, Durick K, Xuong NH, Ten Eyck L, Taylor SS 
and Varughese KI. Regulatory subunit of protein kinase A: structure of deletion mutant 
with cAMP binding domains. Science 269(5225): 807-13, 1995. 
 
 71
Tahallah N, Pinkse M, Maier CS and Heck AJ. The effect of the source pressure on 
the abundance of ions of noncovalent protein assemblies in an electrospray ionization 
orthogonal time-of-flight instrument. Rapid Commun Mass Spectrom 15(8): 596-601, 
2001. 
 
Takio K, Wade RD, Smith SB, Krebs EG, Walsh KA and Titani K. Guanosine cyclic 
3',5'-phosphate dependent protein kinase, a chimeric protein homologous with two 
separate protein families. Biochemistry 23(18): 4207-18, 1984. 
 
Taylor MK and Uhler MD. The amino-terminal cyclic nucleotide binding site of the 
type II cGMP-dependent protein kinase is essential for full cyclic nucleotide-dependent 
activation. J Biol Chem 275(36): 28053-62, 2000. 
 
Taylor SS and Stafford PH. Characterization of adenosine 3':5'-monophosphate-
dependent protein kinase and its dissociated subunits from porcine skeletal muscle. J Biol 
Chem 253(7): 2284-7, 1978. 
 
Wall ME, Francis SH, Corbin JD, Grimes K, Richie-Jannetta R, Kotera J, 
Macdonald BA, Gibson RR and Trewhella J. Mechanisms associated with cGMP 
binding and activation of cGMP-dependent protein kinase. Proc Natl Acad Sci U S A 
100(5): 2380-5, 2003. 
 
Weber IT, Shabb JB and Corbin JD. Predicted structures of the cGMP binding 
domains of the cGMP-dependent protein kinase: a key alanine/threonine difference in 
evolutionary divergence of cAMP and cGMP binding sites. Biochemistry 28(14): 6122-7, 
1989. 
 
Weber IT, Steitz TA, Bubis J and Taylor SS. Predicted structures of cAMP binding 
domains of type I and II regulatory subunits of cAMP-dependent protein kinase. 
Biochemistry 26(2): 343-51, 1987. 
 
Wolfe L, Francis SH and Corbin JD. Properties of a cGMP-dependent monomeric 
protein kinase from bovine aorta. J Biol Chem 264(7): 4157-62, 1989. 
 
Woodford TA, Correll LA, McKnight GS and Corbin JD. Expression and 
characterization of mutant forms of the type I regulatory subunit of cAMP-dependent 
protein kinase. The effect of defective cAMP binding on holoenzyme activation. J Biol 
Chem 264(22): 13321-8, 1989. 
 
Wu J, Jones JM, Nguyen-Huu X, Ten Eyck LF and Taylor SS. Crystal structures of 
RIalpha subunit of cyclic adenosine 5'-monophosphate (cAMP)-dependent protein kinase 
complexed with (Rp)-adenosine 3',5'-cyclic monophosphothioate and (Sp)-adenosine 
3',5'-cyclic monophosphothioate, the phosphothioate analogues of cAMP. Biochemistry 
43(21): 6620-9, 2004. 
 72
 
Zawadzki KM and Taylor SS. cAMP-dependent protein kinase regulatory subunit type 
IIbeta: active site mutations define an isoform-specific network for allosteric signaling by 
cAMP. J Biol Chem 279(8): 7029-36, 2004. 
 
Zhao J, Trewhella J, Corbin J, Francis S, Mitchell R, Brushia R and Walsh D. 
Progressive cyclic nucleotide-induced conformational changes in the cGMP-dependent 
protein kinase studied by small angle X-ray scattering in solution. J Biol Chem 272(50): 
31929-36, 1997. 
 
 
 
 73
CHAPTER THREE: STRUCTURAL CHARACTERIZATION OF PKG USING 
CRYSTALLOGRAPHY 
 
Introduction  
Within the family of cyclic nucleotide-dependent Ser/Thr protein kinases, PKG 
shares the closest sequence homology and domain structure with PKA (Figures 1 A, 2 A). 
In the past, X-ray crystallographic and NMR studies have proven invaluable to 
characterize the structure of PKA. The crystal structure of the catalytic subunit of PKA 
established for the first time the conserved structural features of the protein kinase 
superfamily (Knighton et al., 1991). The catalytic subunit is a globular protein consisting 
of two lobes - a highly dynamic small lobe that serves as an ATP binding site, and a large 
lobe that serves as a framework for the catalytic machinery and also as a docking scaffold 
for target proteins (substrates or inhibitors). The regulatory (R) subunit is highly dynamic 
and functions primarily as a cAMP receptor (Figure 1 C) (Su et al., 1995). The parallel, 
helical dimerization/docking (D/D) domain interacts with scaffold proteins, called A-
kinase anchoring proteins (AKAPs) (Kinderman et al., 2006; Newlon et al., 2001). 
Following this domain is a variable and flexible linker region containing an inhibitor site 
that docks to the active-site cleft of the catalytic (C) subunit and two in-tandem cAMP-
binding domains (A and B). The phosphate-binding cassette (PBC), a helix-loop region 
where cAMP binds, is the most conserved domain among all cyclic nucleotide binding 
proteins, which include PKA/PKG, catabolite activator protein, hyperpolarization-
activated cyclic nucleotide-modulated channel, and exchange protein directly activated 
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by cAMP. The crystal structure of the PKA holoenzyme (Figure 1 D), recently published 
by Kim and colleagues (Kim et al., 2007; Kim et al., 2005), reveals in molecular detail 
the highly dynamic processes and conformational changes that need to occur during PKA 
activation.  
In contrast, the mechanism of PKG activation is not very well described 
structurally. Hydrodynamic and small-angle x-ray scattering techniques have confirmed 
that cGMP binding induces significant conformational changes in the regulatory PKG 
domain (Richie-Jannetta et al., 2006; Wall et al., 2003; Zhao et al., 1997). The parallel, 
alpha-helical interactions of the N-terminal domains (Schnell et al., 2005) have been 
revealed using NMR and support an overall parallel orientation of the dimeric PKG 
holoenzyme (Figures 2 A, B). The structure of other functional domains, such as the 
cGMP binding sites and the catalytic domain, have not been characterized using 
crystallography or NMR.  
Large quantities of protein are generally a pre-requisite for crystallographic 
screens. Since PKA can be easily expressed in bacteria, sufficient quantities can be 
generated for crystallographic studies. Conversely, PKG can only be over-expressed in a 
soluble form in a mammalian expression system (e.g. SF 9 insect cells), which generally 
results in lower protein yields compared to a bacterial expression system. The goal of this 
study was to develop a bacterial expression system for PKG deletion fragments in order 
to yield sufficient quantities of protein for crystallographic studies and in order to 
simplify the existing expression protocol. In addition, full-length PKG as well as deletion 
fragments were tested for crystallization.  
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Results 
Crystallization of full-length PKG 
First, highly concentrated PKG (5 mg/ml; Figure 3 A) was utilized to screen 
various crystallization conditions (Hampton Screen # 1 and #2). Out of several hundred 
conditions, four gave rise to crystals or crystal-like structures (Figures 3 B to E). Mixing 
of full-length PKG with Hampton Screen #1, condition #24 (HS-1/24) (0.2 M Calcium 
chloride dihydrate, 0.1 M Sodium acetate trihydrate pH 4.6, 20% v/v 2-Propanol) resulted 
in 3-dimensional, bi-refringent crystals that were 50 x 30 x 20 µm in size (Figure 3 B). 
The same type of crystals appeared when the enzyme storage buffer (without protein) 
was mixed with buffer #24 (Figure 3 B, insertion). Therefore, these crystals were 
comprised of salt, not protein.  In Figure 3 C, full-length PKG was combined with HS-
1/17 (0.2 M Lithium sulfate monohydrate, 0.1 M Tris hydrochloride pH 8.5 and 30% w/v 
Polyethylene glycol 4,000). After several days of incubation, granula and spherulites (50-
80 µm diameter) appeared. These micro-structures were indicative of protein-crystals, 
since the control-drop with enzyme storage buffer produced a different form of salt 
precipitation (Figure 3 C, insertion). Similarly, addition of PKG to HS-1/16 (0.1 M 
HEPES sodium pH 7.5 and 1.5 M Lithium sulfate monohydrate) gave rise to a mixture of 
protein precipitation and 30-50 µm crystals (Figure 3 D). These crystals most likely 
consist of protein, because the control drop without protein produced a differently shaped 
salt precipitation. When full-length PKG was combined and incubated with HS-1/13 (0.2 
M Sodium citrate tribasic dihydrate, 0.1 M Tris hydrochloride pH 8.5, 30% v/v 
Polyethylene glycol 400), 2-dimensional crystal-plates (50 x 30 µm in size (Figure 3E)) 
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grew after several days. These crystals were most promising, since the control drop was 
lacking any (salt-) crystal formation (Figure 3 E, insertion). Therefore, the crystal-plates 
in Figure 3 E can be attributed to PKG protein. 
 
Deletion fragments of PKG are suitable for bacterial expression and form the basis 
for crystallization 
For X-ray crystallographic studies, vast amounts of protein are necessary to 
screen numerous crystallization conditions. So far, the amount of PKG protein has been a 
limiting factor for crystallization, since PKG can only be expressed in highly 
sophisticated insect cell expression systems (e.g. SF 9). Since it is more challenging to 
produce sufficient amounts of protein in SF9 cells, our goal was to establish a bacterial 
expression system for PKG deletion fragments, focusing on the regulatory domain of 
PKG. These PKG deletion mutants would then form the basis for crystallographic 
studies.  
We first focused on the cGMP-binding site B (Figure 4 A) and cloned three 
different size constructs into the bacterial expression vector pET19b: construct B1 (E227-
G327), B2 (E227-Y336) and B3 (E227-K342). The different constructs were tested for 
expression in E.coli BLR (Figure 4 B). Comparison to non-induced cells revealed that 
constructs B1-B3 could be successfully over-expressed in bacteria with high yields 
(approximately 5 mg per 50 ml E.coli). 
After successfully establishing a bacterial expression system for a single cGMP 
binding site, we attempted to clone both cGMP binding sites into the bacterial vector pET 
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19b (Figure 5 A) and over-express it in bacteria. Two different size constructs have been 
designed, RS3 (Q110-G327) and RS4 (Q110-K342), and both constructs were tested for 
expression and solubility. As shown in Figure 5 B, RS3 and RS4 could both be over-
expressed in E.coli BLR after induction with 0.4 mM IPTG. Comparing samples of 
homogenate, supernatant and pellet of RS4 revealed that it is only partly expressed in a 
soluble form in bacteria (Figure 5 C). About 30% of protein was detected in the pellet 
and could not be recovered. Construct RS4 was over-expressed in bacteria and purified to 
2.5 mg/ml final concentration. Next, RS4 was screened for crystallization using Hampton 
Research Screens #1 and #2. Crystal-clusters were only seen for RS4 in combination with 
0.2 M Calcium chloride dihydrate, 0.1 M Sodium acetate trihydrate pH 4.6 and 20% v/v 
2-Propanol (Figure 5 D). To increase the likelihood of crystal formation in future studies, 
crystallization screens should be repeated using higher protein concentrations. In 
addition, the crystallization condition that resulted in RS4 crystals (Figure 5 D) should be 
refined in varying pH, incubation temperature, salt- and precipitant concentrations.  
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Discussion 
Site-specific mutagenesis, hydrodynamic studies, as well as small angle x-ray 
scattering approaches have been used extensively to gain insight into PKG folding 
(Richie-Jannetta et al., 2006; Wall et al., 2003; Zhao et al., 1997). In this study, we 
attempted to address this question by crystallizing full-length PKG as well as PKG-
derived deletion fragments. As shown in Figures 3 B to E, we were able to obtain PKG 
crystals and crystal-like structures. The crystallization conditions that produced PKG 
crystals (Figure 3 E) or crystal-like structures (Figures 3 C, D) need to be refined in 
future studies by varying pH, incubation temperature, salt- and precipitant concentrations. 
Fine-tuning these conditions and utilizing macro- or micro- seeding may result in 
enlarged PKG crystals that qualify for diffraction and ultimately reveal a structural model 
for PKG. There are still some challenges associated with crystallizing full-length PKG, 
such as protein availability through production in SF9 cells, as generation of well-
diffracting crystals. Therefore, having smaller fragments of PKG serves multiple 
purposes: smaller deletion fragments are more likely to be successfully expressed in 
bacteria, and smaller proteins are also more likely to form crystals that are diffracting to 
high resolution. In addition, removal of the N-terminal domain in the deletion fragments 
prevents PKG-dimer formation as well as autophosphorylation events. The molecular 
structure of the cGMP binding sites could elucidate very elegantly the mechanism of 
cGMP binding and PKG activation. Furthermore, crystals of either full-length PKG or 
smaller PKG fragments could be used for soaking in PKG-inhibitors such as DT2 
(Dostmann et al., 2000; Taylor et al., 2004) and PKG-activators. This would not only 
 79
extend our knowledge about the detailed molecular structure of PKG, but also answer 
fundamental physiological questions about PKG activation and inhibition.  
The static crystal structures will provide essential clues as to the conformational 
versatility of PKG. However, complementary solution methods will be necessary to study 
the dynamics of PKG in a more physiological environment. To meet this challenge, we 
have used a variety of techniques, in addition to crystallography, to probe the structure 
and function of PKG. We have used single point mutants to study cGMP binding and 
kinase activation in vitro (Chapter 2), and non-FRET based indicators to monitor PKG 
activity and cGMP signaling in living cells and in intact tissue (Chapters 4 and 5). Such 
strategies are designed to unravel the complexity of PKG and cGMP signaling networks. 
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Materials and Methods 
Plasmid construction and bacterial expression  
PKG deletion fragments were constructed by inserting different size constructs of 
cGMP binding site B (B1: E227-G327; B2: E227-Y336; B3: E227-K342) or different 
size constructs of the regulatory domain (RS3: Q110-G327; RS4: Q110-K342) of bovine 
PKG I α into the bacterial expression vector pET19b (Novagen). All constructs were 
inserted into the BamHI and EcoRI sites of pET19b, multiplied in E.coli DH5α, and 
expressed in E.coli BLR (invitrogen). To test for bacterial expression, E.Coli BLR 
transformed with PKG-containing pET19b vectors were cultured at 37°C for 12h after 
protein induction with 0.4 mM isopropyl-β-D-thiogalactoside (IPTG). After 
centrifugation, PKG deletion fragment RS4 was purified using cyclic nucleotide affinity 
chromatography as described previously (Feil et al., 1993). Purified PKG deletion 
fragment RS4 (RS 4: 6 mg per 500 ml E.coli) was concentrated using Pall-Filtron 
concentrators to 2.5 mg/ml final concentration and applied for crystallization screens. 
 
Expression in SF9 cells 
Full-length PKG was cloned into the pFAST-BAC mammalian expression vector 
(invitrogen), over-expressed in SF 9 cells and purified using cyclic nucleotide affinity 
chromatography as described previously (Feil et al., 1993). Purified protein (5 mg per 
750 ml SF9-cells) was concentrated using Pall-Filtron concentrators to 5 mg/ml final 
concentration and utilized for crystallization screens. 
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Crystallization 
Hampton Screens # 1 and #2 (Hampton Research, (Jancarik and Kim, 1991)) were 
used to screen various crystallization conditions, mixing protein and buffer in a 1:1 ratio 
and incubating at room temperature for several days using the hanging drop method. As 
control, enzyme storage buffer was mixed with the crystallization buffer, in order to 
distinguish between salt crystals and protein crystals. 
 
  
 
 
 82
Figure Legends 
Figure 1: Structural characterization of cAMP-dependent protein kinase (PKA). (A) 
Schematic representation of PKA. (B) Catalytic subunit with small (white) and large lobe 
(tan) bound to inhibitor peptide and ATP (red) (Taylor et al., 2005).  The consensus site 
peptide RRGAI docks to the active site cleft. (C) Model of the dimeric RIα subunits 
showing the structured domains and the flexible linker (Taylor et al., 2005). The D/D 
domain structure was solved by NMR and the cyclic nucleotide binding domains (CNB 
(A) and (B)) were solved by crystallography. The flexibility of the linker was 
demonstrated by fluorescence anisotropy where the red dots indicate sites where the 
fluorescent probes are attached. (D) Crystal structure of a complex between the 
regulatory (RIα) and catalytic subunits of PKA (Kim et al., 2005).  
 
Figure 2: Domain structure of cGMP-dependent protein kinase (PKG). (A) Schematic 
representation of PKG. (B) Structure of N-terminal dimerization sites (Schnell et al., 
2005). 
 
Figure 3: Crystallization of full-length PKG. (A) 5-20 µg PKG were loaded on 10% SDS-
PAGE. Crystallization of PKG (5 mg/ml) using Hampton Research Screen condition 24 
(B), condition 17 (C), condition 16 (D) and 13 (E). Insertions in the upper left depict a 
mixture of enzyme storage buffer with the screened condition from Hampton Research. 
 
 83
Figure 4: Bacterial expression of cGMP binding site B. (A) Schematic representation of 
PKG highlighting cGMP binding site B (boxed area in green). (B) Comparison of non-
induced (lane 2) and IPTG-induced E.coli BLR cells that were transformed with pET19b-
B1 (lane 3), pET19b-B2 (lane 4) or pET19b-B3 (lane 5). 
 
Figure 5: Crystallization of PKG regulatory domain. (A) Schematic representation of 
PKG highlighting the regulatory domain (boxed area in green). (B) Comparison of non-
induced and IPTG-induced E.coli BLR cells that were transformed with empty pET19b 
vector (lanes 2-3), pET19b-RS3 (lanes 4-5) or pET19b-RS4 (lanes 6-7). (C) Protein  
expression of RS4 was tested for solubility by comparing samples from homogenate (lane 
2), supernatant (lane 3) and pellet (lane 4). (D) Crystallization of RS4 (2.5 mg/ml) using 
condition 24 of Hampton Screen.  
  
 
 84
Figure 1: 
 
 
 
 
 85
Figure 2: 
 
 
 
 86
Figure 3: 
 
 
 
 87
Figure 4: 
 
 
 88
Figure 5: 
 
 
 
 
 
 
 89
References 
 
Dostmann WR, Taylor MS, Nickl CK, Brayden JE, Frank R and Tegge WJ. Highly 
specific, membrane-permeant peptide blockers of cGMP-dependent protein kinase Ialpha 
inhibit NO-induced cerebral dilation. Proc Natl Acad Sci U S A 97(26): 14772-7, 2000. 
 
Feil R, Muller S and Hofmann F. High-level expression of functional cGMP-dependent 
protein kinase using the baculovirus system. FEBS Lett 336(1): 163-7, 1993. 
 
Jancarik J and Kim SH. Sparse matrix sampling: a screening method for crystallization 
of proteins. J Appl Cryst 24: 409-411, 1991. 
 
Kim C, Cheng CY, Saldanha SA and Taylor SS. PKA-I holoenzyme structure reveals 
a mechanism for cAMP-dependent activation. Cell 130(6): 1032-43, 2007. 
 
Kim C, Xuong NH and Taylor SS. Crystal structure of a complex between the catalytic 
and regulatory (RIalpha) subunits of PKA. Science 307(5710): 690-6, 2005. 
 
Kinderman FS, Kim C, von Daake S, Ma Y, Pham BQ, Spraggon G, Xuong NH, 
Jennings PA and Taylor SS. A dynamic mechanism for AKAP binding to RII isoforms 
of cAMP-dependent protein kinase. Mol Cell 24(3): 397-408, 2006. 
 
Knighton DR, Zheng JH, Ten Eyck LF, Ashford VA, Xuong NH, Taylor SS and 
Sowadski JM. Crystal structure of the catalytic subunit of cyclic adenosine 
monophosphate-dependent protein kinase. Science 253(5018): 407-14, 1991. 
 
Newlon MG, Roy M, Morikis D, Carr DW, Westphal R, Scott JD and Jennings PA. 
A novel mechanism of PKA anchoring revealed by solution structures of anchoring 
complexes. Embo J 20(7): 1651-62, 2001. 
 
Richie-Jannetta R, Busch JL, Higgins KA, Corbin JD and Francis SH. Isolated 
regulatory domains of cGMP-dependent protein kinase Ialpha and Ibeta retain 
dimerization and native cGMP-binding properties and undergo isoform-specific 
conformational changes. J Biol Chem 281(11): 6977-84, 2006. 
 
Schnell JR, Zhou GP, Zweckstetter M, Rigby AC and Chou JJ. Rapid and accurate 
structure determination of coiled-coil domains using NMR dipolar couplings: application 
to cGMP-dependent protein kinase Ialpha. Protein Sci 14(9): 2421-8, 2005. 
 
Su Y, Dostmann WR, Herberg FW, Durick K, Xuong NH, Ten Eyck L, Taylor SS 
and Varughese KI. Regulatory subunit of protein kinase A: structure of deletion mutant 
with cAMP binding domains. Science 269(5225): 807-13, 1995. 
 
 90
Taylor MS, Okwuchukwuasanya C, Nickl CK, Tegge W, Brayden JE and Dostmann 
WR. Inhibition of cGMP-dependent protein kinase by the cell-permeable peptide DT-2 
reveals a novel mechanism of vasoregulation. Mol Pharmacol 65(5): 1111-9, 2004. 
 
Taylor SS, Kim C, Vigil D, Haste NM, Yang J, Wu J and Anand GS. Dynamics of 
signaling by PKA. Biochim Biophys Acta 1754(1-2): 25-37, 2005. 
 
Wall ME, Francis SH, Corbin JD, Grimes K, Richie-Jannetta R, Kotera J, 
Macdonald BA, Gibson RR and Trewhella J. Mechanisms associated with cGMP 
binding and activation of cGMP-dependent protein kinase. Proc Natl Acad Sci U S A 
100(5): 2380-5, 2003. 
 
Zhao J, Trewhella J, Corbin J, Francis S, Mitchell R, Brushia R and Walsh D. 
Progressive cyclic nucleotide-induced conformational changes in the cGMP-dependent 
protein kinase studied by small angle X-ray scattering in solution. J Biol Chem 272(50): 
31929-36, 1997. 
 
 
 
 91
CHAPTER FOUR: DIFFERENTIAL PATTERNING OF CGMP IN VASCULAR 
SMOOTH MUSCLE CELLS REVEALED BY SINGLE GFP-LINKED 
BIOSENSORS 
 
Lydia WM Nausch, Jonathan Ledoux, Adrian D. Bonev, Mark T Nelson and Wolfgang R 
Dostmann 
Department of Pharmacology, University of Vermont, College of Medicine, Burlington, 
05405 VT 
 
Corresponding author: Wolfgang Dostmann, Ph.D, University of Vermont, Department 
of Pharmacology, Health Science Research Facility 330, 149 Beaumont Avenue, 
Burlington, VT 05405-0075, USA 
Tel: (802) 656-0381, Fax: (802) 656-4523, EMail: wdostman@uvm.edu 
 
Text: 34 pages; 5 Figures, 3 Tables, 1 supporting information, 4 supporting Figures, 4 
supporting movies. Word and character count: 47,692 
 
Proceedings of the National Academy of Sciences. Jan 8, 105(1): 365-370, 2008. 
 
 92
Abbreviations footnote: cGMP, cyclic-3',5'-guanosine monophosphate; [cGMP]i, 
intracellular cGMP; cAMP, cyclic-3',5'-adenosine monophosphate; VSM, vascular 
smooth muscle; PDE, phosphodiesterase; PKG, cGMP dependent protein kinase; pGC, 
particular guanylyl cyclase; sGC, soluble guanylyl cyclase; NO, nitric oxide; ANP, atrial 
natriuretic peptide; FRET, fluorescence resonance energy transfer; cpEGFP, circular 
permutated EGFP; FlincG, fluorescent indicator of cGMP; DEA-NO, Diethylamine 
NONOate; PROLI-NO, 1-[2-(carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolate 
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Abstract 
Here we report the design of unprecedented, non-FRET based cGMP-biosensors, 
named FlincGs, to assess the dynamics of nitric oxide (NO) and atrial natriuretic peptide 
(ANP) induced synthesis of intracellular cGMP, [cGMP]i.  Regulatory fragments of PKG 
I α, PKG I β, and an N-terminal deletion mutant of PKG I α were fused to circular 
permutated EGFP to generate α-, β-, and δ-FlincG, with high dynamic ranges and 
apparent KD,cGMP values of 35 nM, 1.1 µM and 170 nM, respectively. All indicators 
displayed significant selectivity for cGMP over cAMP, and 1.5 to 2.1 fold increases in 
fluorescence intensity at 510 nm when excited at 480 nm. Surprisingly, FlincGs displayed 
an additional excitation peak at 410 nm. δ-FlincG permitted ratiometric (480/410 nm) 
measurements, with a cGMP specific 3.5 fold ratio change. In addition, δ-FlincG 
presented cGMP association and dissociation kinetics sufficiently fast to monitor rapid 
changes of [cGMP]i in intact cells. In unpassaged, adenoviral transfected vascular smooth 
muscle (VSM) cells, δ-FlincG had an  EC50,cGMP of 150 nM, and revealed transient global 
cGMP elevations to sustained physiological NO (EC50, DEA/NO = 4 nM), and the decay 
phase was dependent on the activity of PDE-5.  In contrast, ANP elicited sustained sub-
membrane elevations in [cGMP]i, which were converted to global cGMP elevations by 
inhibition of PDE-5 by sildenafil.  These results indicate that FlincG is an innovative tool 
to elucidate the dynamics of a central biological signal –cGMP-, and that NO and 
natriuretic peptides induce distinct cGMP patterning under the regulation of PDE-5, and 
hence likely differentially engage cGMP targets. 
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Introduction 
Cyclic 3',5'-guanosine monophosphate (cGMP) has profound effects on cell 
function through actions on cGMP-specific phosphodiesterases (PDEs) and cGMP-
dependent protein kinases (PKGs), as well as through several types of cyclic nucleotide-
activated ion channels (CNGs) (Conti and Beavo, 2007; Francis et al., 2005; Hofmann, 
2005; Hofmann et al., 2005). cGMP is synthesized by two distinct families of guanylyl 
cyclases: i) the natriuretic peptide-specific, plasma membrane associated guanylyl 
cyclases (pGC), and (ii) the nitric oxide (NO) activated, cytosolic soluble guanylyl 
cyclases (sGC) (Cary et al., 2006; Garthwaite, 2005; Kuhn, 2005; Mullershausen et al., 
2005). Intracellular cGMP levels are terminated through the hydrolyzing activities of 
cGMP-specific phosphodiesterases (Conti and Beavo, 2007).  
In recent years, several FRET-based cGMP indicators have been developed in an 
effort to monitor spatio-temporal dynamics of [cGMP]i (Honda et al., 2001; Nikolaev et 
al., 2006; Russwurm et al., 2007). Particularly, Cygnet-type cGMP indicators have 
significantly advanced our understanding of cGMP dynamics in VSM and other cell 
types (Cawley et al., 2007; Honda et al., 2001; Honda et al., 2005; Honda et al., 2005; 
Mongillo et al., 2006; Takimoto et al., 2005). However, FRET-based cGMP indicators 
have limitations. They require a technically laborious dual emission detection system and 
generally show overall low cyan/yellow emission ratio changes in intact cells. 
Furthermore, at low, physiological NO-concentrations (< 10 nM), FRET-based cGMP 
indicators are limited in their use to detect fluctuations in [cGMP]i (Cawley et al., 2007). 
However, recent studies using purified cyclase, intact platelets and cerebellar cells have 
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shown that sGC is activated at low-nanomolar NO concentrations (1 to 10 nM) (Mo et 
al., 2004; Roy and Garthwaite, 2006). FRET-based cGMP indicators are also limited in 
resolving possible compartmentalized intracellular cGMP signaling events using confocal 
microscopy. It was recently suggested that in VSM cells and cardiac myocytes cGMP 
signaling may be spatially segregated and that this functional compartmentalization may 
be the cause of the unique actions of ANP and NO (Castro et al., 2006; Fischmeister et 
al., 2006; Kass et al., 2007; Piggott et al., 2006; Takimoto et al., 2007). The goal of this 
study was to develop previously undescribed, non-FRET biosensors suitable to monitor 
the temporal changes of [cGMP]i in response to low-nanomolar NO or ANP, and to 
investigate the spatial patterning of [cGMP]i, using real-time, confocal imaging 
techniques.  
The concept of non-FRET based biosensors, containing a single GFP-based 
fluorescence unit was first described by Tsien and colleagues with the development of 
Ca2+-sensitive ‘camgaroos’, by placing calmodulin at an insertion-permissive site within 
the β sheets of GFP (Baird et al., 1999). Subsequently, circularly permutated EGFP 
(cpEGFP) advanced non-FRET based biosensors even further and gave rise to the 
development of ‘GCaMP’-type Ca2+ indicators, in which the Ca2+-dependent interaction 
between calmodulin and its specific binding protein M13 was directly translated into 
conformational changes and an increase in fluorescence intensity of the single fluorescent 
molecule cpEGFP (Nakai et al., 2001; Tallini et al., 2006). We adopted this concept of 
non-FRET biosensors to design cGMP indicators, called FlincGs (fluorescent indicators 
of cGMP). FlincG indicators are composed of cpEGFP, N-terminally fused to regulatory 
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domain fragments of PKG. The overall favorable kinetic and spectroscopic 
characteristics of this single emission detection system permits for the first time the direct 
examination of local cGMP dynamics in response to low-nanomolar NO or ANP in VSM 
cells in real-time.  
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Results and Discussion 
Bioengineering FlincG biosensors from type I PKG. 
FlincGs are composed of two in-tandem, PKG derived cGMP binding sites fused 
to the N-terminus of cpEGFP (Figure 1 A). In contrast to GCaMP-type calcium indicators 
(Nakai et al., 2001), FlincGs do not require intramolecular protein-protein interactions 
between separate domains. Instead, dose-dependent binding of cGMP to both receptor 
domains was sufficient to increase fluorescence intensity in cpEGFP (Figure 1 C, inset). 
Previous studies using hydrodynamic and small-angle x-ray scattering techniques support 
our findings that cGMP binding to the regulatory domain of PKG I induces substantial 
conformational changes (Richie-Jannetta et al., 2006; Wall et al., 2003; Zhao et al., 
1997). α-FlincG was developed by attaching the entire regulatory domain of PKG I α 
(residues 1-356) to cpEGFP (Figure 1 B). cGMP increased fluorescence intensity of this 
construct by up to 1.5-fold,  with an apparent KD of 35 nM (Figure 1 C) and with an 
approximately 1,100 fold selectivity for cGMP over cAMP (Table 1).  
To increase the dynamic range of [cGMP]i detection, we took advantage of the 
fact that the activation constants of PKG I α and I β shift from 75 nM to approximately 
1.0 to 1.8 µM (Ruth et al., 1991; Ruth et al., 1997; Wolfe et al., 1989). PKG I α and I β 
are genetic splice-variants and consist of different N-termini, but are virtually identical 
within their cGMP binding and catalytic domains (Ruth et al., 1991). Thus, we developed 
β-FlincG, by connecting the regulatory domain of PKG I β to the N-terminus of cpEGFP 
(Figure 1 B). As predicted, this FlincG variant demonstrated a shifted cGMP binding 
constant of 1.1 µM (Figure 1 C, Table 1), indicating the significance of the N-terminus 
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for modulating cGMP binding affinities. Interestingly, removal of the entire N-terminal 
domain (∆1-77) of PKG I α resulted in δ-FlincG, which exhibited an apparent KD of 170 
nM. This result is in accordance to an analogous PKG I α deletion fragment, ∆1-77/352-
670 for which a similar cGMP binding constant (KD = 218 nM) has been reported 
(Dostmann et al., 1996). This finding further supports the concept that the N-terminal 
domain of PKG, not the catalytic domain, primarily modulates cGMP binding affinities 
of the FlincG indicators. Interestingly, the C-terminus of FlincGs did not affect 
fluorescence intensity changes. Neither the linker sequence shown in Figure 1 B, which 
was the product of a randomized cloning approach, nor attachment of the PKG catalytic 
domain, or complete removal of any C-terminal appendage had any effect on overall 
fluorescence intensity changes (data not shown).  
Under cell-free conditions, α- and β-FlincG exhibited maximal 1.5 and 2.1-fold 
intensity changes, respectively (Figure 1 C, Table 1).  When expressed in VSM cells, the 
maximal fluorescence increases of α- and β-FlincG were reduced to about 1.2-fold, 
although these indicators retained high NO-sensitivity (EC50, DEA-NO = 0.3 and 12 nM, 
respectively) (Table 2; Figure 1 D). Both biosensors contain their respective N-terminal 
PKG dimerization sequences, which may give rise to interactions with endogenous PKG 
and thus decreases their observed maximal intensity changes (Figure 1 D, Table 2).  In 
support of this idea, co-immunoprecipitation experiments demonstrated formation of 
mixed dimers between wild-type PKG and α-, or β-FlincG (supp. Figure 1). However, δ-
FlincG did not display any interaction with wildtype PKG, because it lacks the N-
terminal dimerization domain (supp. Figure 1). Hence, we did not observe a reduction of 
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maximal fluorescence intensity when comparing purified δ-FlincG to indicator expressed 
in intact VSM cells (Figures 1 C, E), whilst  retaining high NO sensitivity (EC50, DEA-NO = 
4 nM; Figure 1 E). This indicator was also highly selective for cGMP over cAMP (> 280 
fold, Table 1). 
Recently published FRET cGMP-sensors by Russwurm and colleagues (Russwurm et al., 
2007) display a comparable maximal FRET ratio change of 75 % for recombinant 
protein. In living cells however, all FRET-indicators published so far, exhibit a 
significant decrease in maximal FRET ratio change, ranging from 35 to 45 % (Cawley et 
al., 2007; Honda et al., 2001; Nikolaev et al., 2006; Russwurm et al., 2007). In contrast, 
FlincG cGMP biosensors have been designed to minimize interactions with endogenous 
proteins and to maintain maximal fluorescence intensity changes in living cells while 
retaining nanomolar NO sensitivity. Since δ-FlincG exhibits all these favorable 
characteristics in living cells, we selected δ-FlincG as indicator suitable for studying 
intracellular cGMP dynamics. 
 
Kinetic, spectral analysis and environmental stability of δ-FlincG 
        A more refined spectral analysis revealed that in addition to the 491 excitation 
maximum, δ-FlincG displayed a second, blue-shifted excitation peak at 410 nm (Figure 2 
A). Furthermore, these excitation maxima at 410 and 491 nm respond differentially in 
response to 1 µM cGMP.  It should be noted, that all FlincG indicators possessed this 
secondary 410 nm excitation maximum (data not shown), but only for δ-FlincG cGMP 
decreased the emission intensity at 410 nm 0.5-fold, with a corresponding emission 
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maximum at 507 nm (Figure 2 B). In addition, excitation at 480 nm yielded an emission 
maximum at 511 nm (Figure 2 C) with an overall 1.75-fold fluorescence intensity 
increase. Thus, our results are in contrast to the excitation emission spectra of EGFP and 
previous cpEGFP based indicators, such as camgaroos and GCaMPs, which display only 
one excitation maximum at 489 nm (Baird et al., 1999; Griesbeck et al., 2001; Nakai et 
al., 2001). 
Based on its dual excitation spectrum, δ-FlincG offers several technical 
alternatives to previous FRET-based cGMP imaging techniques. First, the two excitation 
wavelengths may be combined and analyzed ratiometrically (480/410 nm excitation), 
similar to the Ca2+ indicator Fura (Grynkiewicz et al., 1985). As a result, the overall ratio 
change increased up to 3.5 fold in vitro, and the overall apparent KD,cGMP was 488 nM, 
with approximately 100-fold selectivity for cGMP over cAMP (Figure 2 D, Table 1).  
Second, a single wavelength excitation system could be utilized by employing a 410/510 
nm excitation/emission detection profile. However, for the initial experiments with δ-
FlincG, the single wavelength approach (480/510 nm excitation/emission) was used, 
because it is faster, has decreased risk of photo-bleaching, superior cGMP/cAMP 
selectivity, and an advantageous apparent cGMP binding constant of 170 nM (Figure 1 C 
and Table 1).  Nonetheless, in future studies, the ratiometric approach (Figure 2 D) would 
present a number of significant inherent advantages, including the determination of 
[cGMP]i.  
To examine further δ-FlincG’s utility as a [cGMP]i-biosensor, we investigated its 
environmental stability under varying pH conditions (supp. Figure 2). Previously reported 
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cpGFP based biosensors, such as camgaroos and GCaMPs, have displayed significant pH 
sensitivity under physiological conditions with pKa values of 8.9 and 7.1, respectively 
(Baird et al., 1999; Nakai et al., 2001). Elaborate mutational approaches have been 
undertaken to reduce the environmental sensitivity of GFP and GFP-based variants. So 
far, only Citrine, a yellow fluorescent protein (YFP) -based mutant, has been reported 
with superior chloride and pH stability (pKa 5.7) compared to previous YFPs (Griesbeck 
et al., 2001). In comparison, our results indicate that δ-FlincG did not require mutational 
optimization to accomplish resistance to small changes in pH under physiological 
conditions (pKa 6.1).  
An important requirement for a biosensor is to have fast kinetics so that 
intracellular temporal and spatial changes can be accurately monitored. Stopped-flow 
experiments revealed a fast rate of cGMP association (kon = 5.9 x 10
6 s-1M-1; t1/2 = 0.12 s) 
(Figure 3 A, Table 3). The dissociation constant determined by protein dilution was 
equally rapid (koff = 4.2 s
-1; t1/2 = 0.16 s) (Figure 3 B, Table 3). These rate constants 
ensure that the rate limiting step for detecting [cGMP]i does not occur at the level of 
cGMP association to or dissociation from the biosensor. Equally advantageous, δ-FlincG 
should not act as a sink for [cGMP]i, because its cGMP binding constant (170 nM) is not 
significantly different from its major endogenous receptors PKG I α and PDE 5 in 
vascular smooth muscle (Ruth et al., 1991; Zoraghi et al., 2005). Superior spectral 
characteristics, environmental stability and fast association/dissociation kinetics should 
enable δ-FlincG to capture the rapid rise and fall of [cGMP]i in living VSM cells. 
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Intracellular properties of δ-FlincG in vascular smooth muscle cells 
Recently, we reported that primary, unpassaged VSM cells from rat aorta retain 
the expression of key cGMP-signaling enzymes, such as PKG I, sGC and PDE5 (Cawley 
et al., 2007). Transfection of VSM cells with δ-FlincG adenovirus resulted in an even 
cytosolic distribution and nuclear exclusion of the indicator, with a 90% efficiency (inset, 
Figure 4 A). To determine the apparent affinity of intracellular δ-FlincG for cGMP, VSM 
cells were permeabilized with β-escin and the cells were exposed to different levels of 
cGMP in  Ca2+-free imaging buffer.  Half-maximal fluorescence increases occurred at 
150 nM cGMP (Figure 4A), similar to the value obtained for the purified biosensor (170 
nM; Figure 1 C).  With this approach, the level of intracellular cGMP can be estimated 
from the fractional change in fluorescence. 
An important criterion for intracellular cGMP sensors is that they exhibit  
appropriately high sensitivity to NO, as previously reported for sGC (half-maximal NO:  
1.7 nM for the  purified enzyme, 11 nM for intact platelets,10 nM for cerebellar cells) 
(Mo et al., 2004; Roy and Garthwaite, 2006). DEA-NO and PROLI-NO were used as 
NO-donors due to their overall favorable fast chemistry of NO-release (see Methods).  
DEA-NO (0.75 to 6.50 nM) induced concentration-dependent, transient increases in 
[cGMP]i, corresponding to 10 nM  to 1 µM (Figures 4 A, B). The corresponding half 
activation constant (EC50,DEA-NO) was 4 nM (Figure 1 E; Table 2). Similarly, transient and 
highly reproducible [cGMP]i changes were observed with 25 nM PROLI-NO (EC50, PROLI-
NO = 16 nM; Table 2; Figure 4 C). In contrast to NO-stimulated sGC, activation of the 
plasma membrane associated guanylyl cyclase pGC-A using atrial natriuretic peptide 
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(ANP) resulted in sustained levels of [cGMP]i (Figure 4 D), as demonstrated previously 
in VSM cells using radio-immunoassays (Hamet et al., 1989; Leitman et al., 1988; 
Winquist et al., 1984). These results promote δ-FlincG as exceptional biosensor for 
physiological (low-nanomolar) NO- and ANP-induced cGMP dynamics in VSM cells. 
NO-induced elevation of [cGMP]i requires activation of sGC.   ODQ (10 µM), a 
specific inhibitor of sGC activation (Brunner et al., 1995; Garthwaite et al., 1995; 
Schrammel et al., 1996),  prevented the PROLI-NO (50 nM) induced increase of cGMP 
(Figure 4 E), indicating that the observed rise in [cGMP]i is indeed due to NO-induced 
activation of sGC.  The [cGMP]i also depends on its hydrolysis by PDE-5.  Sildenafil, a 
PDE-5 specific inhibitor (Corbin et al., 2003; Turko et al., 1999), greatly slowed  the 
decay in [cGMP]i in response to PROLI-NO (12 to 200 nM), supporting the concept of a 
dynamic interplay between sGC production  and PDE-5 mediated hydrolysis of cGMP  
(Figure 4 F).  
 
Spatial and temporal dynamics of NO- and ANP- induced cGMP signaling in δ-FlincG 
transfected vascular smooth muscle cells 
          Our current understanding of the intracellular distribution of cGMP derives from 
the fact that the predominant soluble guanylyl cyclase isoform sGC-α1β1 is largely 
cytosolic, hence [cGMP]i should be cytosolic as well (Mullershausen et al., 2005). The 
natriuretic peptides ANP, BNP and CNP, in contrast, specifically activate plasma 
membrane associated guanylyl cyclases pGC-A and pGC-B and thus, may give rise to a 
distinct spatial pattern of [cGMP]i (Fischmeister et al., 2006; Kass et al., 2007). However, 
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the spatial distribution of [cGMP]i in response to NO and ANP has never been studied by 
the means of high resolution confocal imaging techniques. FlincG-indicators should 
permit the measurement of cGMP patterns in living cells.  
        A physiological dose of 1.5 nM NO induced a global, but transient, elevation in 
[cGMP]i  (Figures 5 A, B; supp. Movie 1), similar to measurements conducted with lower 
resolution, epi-fluorescence microscopy (Figure 4 B, C). The membrane-permeant cGMP 
analog (8-Br-cGMP, 50 µM) was applied to VSM cells and a uniform increase in 
fluorescence was observed (supp. Movie 2), indicating homogenous expression of δ-
FlincG in VSM cells. Forskolin (100 nM), which specifically activates the cAMP 
signaling pathway, had no effect on fluorescence intensity (supp. Movie 3), consistent 
with δ-FlincG selectivity for cGMP over cAMP.  
In contrast to the transient NO-evoked [cGMP]i patterns, application of ANP (10 nM) 
induced sustained synthesis of at least 1 µM [cGMP]i (Figures 5 C, D). This finding is in 
agreement with our results shown in Figure 4 D, although different imaging techniques 
(epi- versus confocal microscopy) give rise to variations in the onset of ANP response 
(mean lag time: 25 ± 4 sec, Figure 5C; 45 ± 10 sec, Figure 4D). ANP induced local, 
spatially segregated patterns of [cGMP]i at the plasma membrane of single VSM cells 
(Figure 5 D; supp. Movie 4). To address spatial patterning due to uneven indicator 
expression and cell movement, which may present potential problems in single 
wavelength intensity measurements, we analyzed three-dimensional surface plots 
(Supporting Figure 3) indicating uniform cellular distribution of δ-FlincG (from Figures 
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5 A and D). Supporting Figure 4 verifies that the cell morphology does not change over 
time after NO or ANP application and that the cells do not move. 
Spatially-confined cGMP signaling may be a combination of both local cGMP 
synthesis and local degradation at the membrane. Recently, compartmentalized [cGMP]i 
was reported in cardiac myocytes through specific activation of pGC by natriuretic 
peptides (Castro et al., 2006; Mongillo et al., 2006; Takimoto et al., 2007). These studies 
also suggested that cGMP specific PDEs maintain these local patterns of [cGMP]i elicited 
through pGC. Our results indicate that ANP (10 nM) induced cGMP synthesis is 
sustained and spatially confined in VSM cells (Figures 5 C, D). This spatial localization 
in response to ANP was abolished, when VSM cells were preincubated with the PDE-5 
inhibitor, sildenafil (Figure 5 E). Instead, a global increase in [cGMP]i was observed, 
indicating that degradation of cGMP by PDE-5 prevents the cell’s interior from 
experiencing an elevation of cGMP. These ANP-produced sub-membrane cGMP 
elevations suggest local targeting of sub-membrane targets such as the calcium-sensitive 
(BK) channel and SERCA-regulatory protein, phospholamban (Porter et al., 1998; 
Robertson et al., 1993). 
In conclusion, FlincG represents a previously undescribed generation of cGMP 
biosensors that excels in monitoring [cGMP]i in response to physiological (low-
nanomolar) NO concentrations. FlincG should ultimately be suitable for development of 
tissue-specific generation of transgenic mice with endogenous cGMP indicators, as has 
been done recently for calcium sensing with GCaMP (Ji et al., 2004; Tallini et al., 2006).  
The ratiometric possibilities of FlincG should enhance its versatility.  FlincG revealed the 
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differential role of PDE-5 in the modulation of global cGMP in response to NO donors, 
and the spatial spread of cGMP away from the cell membrane in response to ANP.  
FlincG holds the promise of unraveling the complex interplay between cGMP and 
calcium signaling near the cell membrane. 
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Materials and Methods 
Fluorescence measurements in cultured vascular smooth muscle cells (P0) 
VSM cells were harvested from rat aortic tissue and cultured as described previously 
(Cawley et al., 2007). For transfection, 100 µl of adenovirus (107 to 109 per ml titer) were 
applied to 50% confluent VSM cells (P0) and incubated 24 to 48h at 37°C, 5% CO2 until 
a 90 % transfection efficiency in VSM cells was achieved. Epi-fluorescence imaging was 
performed by incubating cells in imaging buffer (10mM TES (pH 7.4), 1 g/L D-glucose, 
Hank’s Balanced Salt Solution (HBSS, Mediatech, Inc., Herndon, VA) at 37°C using a 
Delta T4 open culture system (Bioptechs, Butler, PA). A Nikon Diaphot 200 microscope 
outfitted with a Nikon 40x/1.30 oil objective, a cooled charge-coupled device camera 
(ORCA ER; Hamamatsu, Japan), and a mercury-halide lamp, X-CITE 120 (EXFO 
Photonics, Toronto, ON), were used to image individual cells with 3 seconds 
acquisitions. Imaging of FlincG indicators was controlled by Metafluor 6.2 software 
(Universal Imaging, Media, PA) using a D480/20m excitation filter, 505drxr dichroic 
mirror and D535/30m emission. For confocal imaging, P0 VSM cells were imaged using 
a spinning disk confocal system (Andor) outfitted on a Nikon E600SN microscope with a 
60x water dipping objective (NA 1.0), and iXon ENCCD DVB camera with 5 frames/sec 
acquisition speed and 64 msec exposure time exciting with a solid state laser at 488 nm, 
and collecting the emission at 510 nm. Data analysis was performed with custom written 
software developed by Dr. Adrian Bonev. For confocal microscopy, cGMP responses 
were investigated upon local application (5 to 50 µl) and subsequent diffusion of 
DEA/NONOate (Calbiochem), PROLI/NONOate (Cayman Chemicals), ANP (Sigma), 
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Sildenafil (Pfizer), ODQ (Sigma), 8-Br-cGMP (BioLog) and Forskolin (Sigma). 
Approximately 75% of the data collected were rejected due to cell movement and 
morphology changes during the course of the experiments. For epi-fluorescence 
microscopy, chemicals were distributed evenly by mixing with imaging buffer. 
Calibration of adenoviral transfected VSM cells was performed in Hepes-buffered, Ca2+-
free PSS pH 7.4. VSM cells were permeabilized with 20 µM β-escin, exposed to 
increasing cGMP concentrations (0 to 2 µM) and analyzed using the epi-fluorescence 
microscope facility. For NO-titration, δ-FlincG transfected VSM cells were exposed to 
0.4 nM - 500 nM DEA-NO (t1/2 = 2.4 min at 37°C, pH 7.4), or to 1.5 nM - 2 µM PROLI-
NO (t1/2 = 1.8 sec at 37°C, pH 7.4). Data were analyzed using the Metafluor software and 
dose-response curves were calculated with GraphPadPrism.  
Further methods are provided in supporting information 1. 
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Table 1: cGMP and cAMP selectivity of recombinant FlincG biosensors 
FlincG isoform (F/F0)max KD,cGMP [µM] KD,cAMP [µM] cGMP/cAMP 
Alpha1 1.55 ± 0.05 [4] 0.035 ± 0.010 [4] 40 ± 8 [3] 1140 
Beta1 2.05 ± 0.03 [5] 1.100 ± 0.050 [5] 31 ± 10 [4] 30 
Delta1 1.75 ± 0.03 [5] 0.170 ± 0.020 [5] 48 ± 10 [4] 280 
Delta2 3.50 ± 0.06 [4] 0.488 ± 0.004 [4] 48 ± 10 [4] 100 
1: single excitation at 480 nm, emission at 510 nm (Fig. 1C); 2: ratiometric excitation at 410 and 480 
nm, emission at 510 nm (Fig. 2D); the values represent the mean ± SEM of n Numbers of 
experiments (shown in brackets);0 
 
 
 
Table 2: NO-titration and Calibration of FlincG biosensors in VSM cells 
FlincG isoform EC50, DEA-NO [nM] EC50, PROLI-NO [nM] (F/F0)max EC
1
50, cGMP [nM] 
Alpha 0.3 ± 0.2 [6] ─ 1.12 ± 0.08 ─ 
Beta 12 ± 0.4 [6] ─ 1.19 ± 0.06 ─ 
Delta 4 ± 0.5 [8] 16 ± 2 [6] 1.75 ± 0.03 150 ± 12 [4] 
1: calibration for cGMP in β-escin permeabilized VSM cells; the values represent the mean ± SEM of n 
Numbers of experiments (shown in brackets); 
 
 
Table 3: cGMP association and dissociation kinetics 
 
FlincG isoform kon [s
-1M-1] t1/2
1 [s] koff [s
-1] t1/2
2 [s] 
Delta 5.9 x 106 [4] 0.12 [4] 4.2 [3] 0.16 [3] 
1: t1/2 cGMP association; 
2: t1/2 cGMP dissociation; the values represent the mean 
± SEM of n Numbers of experiments (shown in brackets); 
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Figure legends: 
 
Figure 1: Characterization of FlincG biosensors as recombinant proteins and in VSM 
cells. (A) Schematic architecture: fusion of regulatory fragments of PKG I to cpEGFP 
induces cGMP dependent changes in fluorescence emission intensity. (B) Domain 
structure: α-, β- and δ-FlincG utilize regulatory fragments of PKG I α and PKG I β. (C) 
cGMP dose response curves for α-, β- and δ-FlincG (Table 1); inset: cGMP dose-
dependent increase in fluorescence intensity shown for α-FlincG. NO-titration of (D) α- 
and β-FlincG and (E) δ-FlincG in single VSM cells using epi-fluorescence microscopy 
(see Table 2). 
 
Figure 2:  Spectral analysis of δ-FlincG. (A) Excitation spectrum of δ-FlincG in presence 
and absence of 1 µM cGMP detected at 510 nm. Emission spectra excited at (B) 410 and 
(C) 480 nm in the presence and absence of 1 µM cGMP. (D) Ratiometric (480/410 nm) 
dose response curves for cGMP and cAMP detected at 510 nm.  
 
Figure 3: cGMP binding kinetics of δ-FlincG. (A) cGMP association kinetics using 
stopped-flow fluorometry. Slopes represent the initial association velocities at different 
cGMP concentrations (inset). (B) cGMP dissociation kinetics using a dilution protocol 
(see Methods). Intensity changes were detected using a fluo-spectrophotometer.  
 
Figure 4: Temporal dynamics of cGMP in VSM cells. (A) Calibration of δ-FlincG. 
Adenovirus-transfected VSM cells (inset) were permeabilized with β-escin and exposed 
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to increasing cGMP concentrations (25 nM - 2 µM). (B, C) Temporal cGMP dynamics in 
VSM cells were analyzed upon addition of 0.75 - 6.5 nM DEA-NO (B), 25 nM PROLI-
NO (C) and 50 nM ANP (D) using epi-fluorescence microscopy . (E, F) Effects of ODQ 
and Sildenafil on δ-FlincG-transfected VSM cells. Cells were exposed repeatedly to 50 
nM PROLI-NO in presence and absence of 10 µM ODQ (E) and to 12 to 200 nM PROLI-
NO in presence of 50 µM Sildenafil (F). For each experimental series, n numbers are 4 to 
10.  
 
Figure 5: Spatial analysis of the NO and ANP pools of cGMP in δ-FlincG transfected 
VSM cells. [cGMP]i in response to (A, B) 1.5 nM DEA-NO and (C, D) 10 nM ANP 
using confocal microscopy. Regions of interest and their corresponding intensity traces 
are indicated with arrows and corresponding color boxes. Acquisition speed = 5 
frames/sec; exposure time = 64 msec. (E) Application of 10 nM ANP after preincubation 
with 100 µM Sildenafil. For each experimental series, n numbers are 4 to 6.  
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Supporting Information 1: 
Materials and Methods 
Plasmid construction and bacterial expression  
FlincG variants were constructed by fusing the regulatory domains of bovine PKG I α (1-
356, α-FlincG), PKG I β (1-372, β-FlincG), or a deletion mutant of PKG I α (77-356, δ-
FlincG) to the 5’ end of circular permutated EGFP (cpEGFP 149-144, (Nakai et al., 
2001)) by overlapping PCR. For bacterial expression, PKG regulatory domains were 
preceded by an XhoI site, and a start codon (ATG). cpEGFP 149-144 was connected at 
the 3’ end to a 17 aminoacid sequence (LSDFNIIDTLGVGGFGR) by overlapping PCR 
and was followed by a stop codon and an EcoRI site. The entire FlincG coding sequence 
was inserted into the XhoI and EcoRI sites of pRSET-A, multiplied in E.coli DH5α and 
expressed in E.coli BLR. Similarly, mammalian adenoviral FlincG constructs were 
preceded at the 5’end by a BamHI site and a Kozak sequence (ACCATGG), inserted into 
the BamHI and EcoRI sites of pENTR vector and sub-cloned into pAd-DEST (ViraPower 
adenoviral expression system, invitrogen). For in vitro studies, E.Coli BLR transformed 
with FlincG-containing pRSET-A vectors were cultured at 25°C for 12h after protein 
induction with 0.4 mM isopropyl-β-D-thiogalactoside (IPTG). After centrifugation, 
FlincG variants were purified using cyclic nucleotide affinity chromatography as 
described previously (Dostmann et al., 2000; Feil et al., 1993).  
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In vitro characterization 
Excitation spectra (detected at 510 nm) and emission spectra (excited at 410 or 480 nm) 
were taken using a fluorescence spectrophotometer F4500 (Hitachi, Tokyo, Japan). 200 
nM purified FlincG was combined with increasing concentrations of cGMP (0-10 µM) or 
cAMP (0-100 µM) to generate cNMP dose response curves. For pH titration experiments 
at 200 nM protein concentration, phosphate buffer (for pH 6.5) was replaced with either 
citrate (for pH 5 to 6), Hepes-buffered HBSS (for pH 7 to 8), or with glycine (for pH 8.5 
to 9). The pH-titration was calculated for each pH point by monitoring the baseline (F0) 
in absence of cGMP, and by determining the increase in fluorescence (F) in presence of 1 
µM cGMP. This approach represents the difference between zero-cGMP and saturating 
cGMP depending on various pH conditions. Kinetic measurements for cGMP association 
were performed utilizing a stopped-flow instrument (BioLogic Science 
Instruments µSFM-20, France). Typically, four independent mixing experiments (10 µM 
protein, 0 to 2 µM cGMP) were averaged before mono-exponential fitting with a Simplex 
routine in Bio-Kine (v. 3.0) proprietary software provided by BioLogic. cGMP 
dissociation kinetics were determined by mixing 500 nM FlincG protein and 150 nM 
cGMP, followed by subsequent > 5 fold dilution in Hepes-buffered HBSS pH 7.4 to final 
cGMP concentrations below 30 nM. The intensity changes indicative of cGMP 
dissociation were recorded using the fluorescent spectrophotometer F4500 (Hitachi, 
Tokyo, Japan). For immunoprecipitation studies, a mixture of 5 µg FlincG protein in 
PSS, 0.1 % NP-40 and 5 µg protein of the corresponding PKG isoform was combined 
with 2 µg rabbit anti-GFP antibody (Invitrogen, Molprobes) and incubated at 25°C for 30 
 119
minutes. The protein-protein complex was precipitated with Protein A/G beads and was 
washed > 3 times with PBS, 0.1% NP-40 buffer. Beads were resuspended in Laemmli 
buffer and subjected to 10 % SDS-PAGE.  
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Supporting Figure legends 
Supporting Figure 1: 10 % SDS-PAGE showing the co-immunoprecipitation of FlincG 
variants with their corresponding PKG isoforms using a rabbit anti-GFP antibody.
 
Supporting Figure 2: pH titration of normalized fluorescence. For each pH point, the 
baseline (F0) was monitored in absence of cGMP, and the increase in fluorescence (F) 
was determined in presence of 1 µM cGMP. 
 
Supporting Figure 3: 
Uniform distribution of fluorescence intensity of δ-FlincG in VSM cells. (A, C) Images 
showing the distribution of fluorescence intensity in VSM cells represented in Figures 5 
A (NO) and D (ANP) at time points zero. (B, D) Three-dimensional surface plots. X- and 
Y-axes represent the orientation of the cells and the Z-axis shows the fluorescence 
intensities.  
 
Supporting Figure 4: 
Cell morphology of δ-FlincG transfected VSM cells. (A, B) Fluorescence images of 
VSM cells depicted in Figures 5 A and D. Dotted lines trace the cell shape over the time-
course of the experiment. Arrows indicate the regions of interest in Figure 5. The insets 
in (B) magnify the region of interest and verify the absence of cellular movement and 
morphology changes over time.  
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Supporting Movie 1: Application of 1.5 nM DEA-NO to δ-FlincG transfected VSM cell 
Supporting movie 2: Application of 50 µM 8-Br-cGMP to δ-FlincG transfected VSM cell 
Supporting movie 3: Application of 100 nM Forskolin to δ-FlincG transfected VSM cell.  
Supporting movie 4: Application of 10 nM ANP to δ-FlincG transfected VSM cells;
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Supporting Figure 1: 
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CHAPTER FIVE: NON-GENETIC DELIVERY SYSTEM FOR NOVEL cGMP-
BIOSENSORS INTO INTACT ARTERIES REVEALS cGMP DYNAMICS IN 
RESPONSE TO NITRIC OXIDE AND ATRIAL NATRIURETIC PEPTIDE. 
 
Introduction 
Nitric oxide (NO) and atrial natriuretic peptide (ANP) were first suggested to 
regulate vascular smooth muscle tone more than 25 years ago. In 1980, Furchgott & 
Zawadzki (Furchgott and Zawadzki, 1980) first described endothelium-dependent 
relaxation, a phenomenon whereby acetylcholine relaxes isolated preparations of blood 
vessels only if the vascular endothelium lining the vessels is present and intact. 
Subsequent studies revealed that acetylcholine and other agents (including bradykinin, 
histamine and 5-hydroxytryptamine) release a transferable factor (endothelium-derived 
relaxing factor, EDRF) which is unstable, acts via stimulation of the soluble guanylate 
cyclase and is inhibited by hemoglobin and methylene blue (Furchgott et al., 1984). 
Several years later, Furchgott as well as Ignarro proposed that EDRF might be nitric 
oxide (Furchgott, 1988; Ignarro et al., 1988). Since then, the vasodilatory effect of NO 
has been studied in great detail, and it is now known that it is caused by a soluble 
guanylyl cyclase-mediated increase in [cGMP]i (Mullershausen et al., 2005). Another 
regulatory factor for vascular smooth muscle tone was discovered in 1981, when Adolfo 
de Bold isolated a potent diuretic and natriuretic factor from rat atrial extracts (de Bold et 
al., 1981). Atrial natriuretic peptide (ANP) has been shown to bind to the membrane-
bound, particulate gunalylyl cyclase A (GC-A), thereby increasing [cGMP]i (Garbers, 
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1991; Garbers and Lowe, 1994). Although several methods exist to detect cGMP in vitro, 
such as biosensors (Honda et al., 2001; Nikolaev et al., 2006; Russwurm et al., 2007), 
radio-immunoassays (Brooker et al., 1979), patch clamping (Castro et al., 2006) and 
patch cramming (Trivedi and Kramer, 1998), it has been challenging to follow [cGMP]i 
dynamics in intact tissue under near-physiological conditions. Commonly used myograph 
studies are suitable to monitor changes in vessel diameter in response to various stimuli, 
thereby indirectly predicting fluctuations in cGMP and calcium dynamics. However, 
there is growing demand for methods to directly detect [cGMP]i in intact arteries. 
Recently, FRET-based cGMP biosensors (Cygnets) were permanently fused to membrane 
permeable peptides (MPP) and shown to be fully functional in cultured VSM cells and in 
intact vessels (Honda et al., 2005). However, these FRET-based indicators have limited 
utility in studying spatio-temporal cGMP dynamics in intact tissue, since they display 
overall low FRET-ratio change in cells, low responsiveness to physiological NO and 
ANP concentrations, and have limited use for high-speed, real-time confocal microscopy. 
These restrictions prompted us to develop a non-genetic delivery system for our novel, 
non-FRET cGMP biosensors, FlincGs (Chapter 4), utilizing intact arteries as a model 
system. Here, we report for the first time a non-FRET based cGMP biosensor suitable to 
detect NO- and ANP-dependent [cGMP]i responses in cerebral arteries.  
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Results and discussion 
Previously, several genetic methods, as well as viral delivery systems, have been 
reported to translocate small nucleotides or plasmids into intact tissue (Bolz and Pohl, 
2003; Earley et al., 2005; Tang et al., 2003; Yao and Wang, 1995; Zhang et al., 2005). 
Since all these methods have limited use to translocate large-size plasmids into intact 
tissue and require long incubation times (several days) for successful delivery, we have 
used a different approach in this study. Npys-TAT, a 2,2’-(5-nitropyridine (Npys)) 
activated form of the membrane-permeable TAT-peptide (Rabanal, 2003), was mixed 
with purified α-FlincG protein in vitro and the activated TAT peptide bound reversibly to 
surface cysteines of α-FlincG (Figure 1 A). TAT-labeling of α-FlincG preserved overall 
cGMP (Ka = 40 ± 3 nM) over cAMP (Ka = 54 ± 8 µM) selectivity and maximal 1.35-fold 
fluorescence intensity change of the cGMP biosensor, indicating that the chemical 
labeling process does not interfere with critical FlincG folding to allow detection of 
[cGMP]i (Figure 1 B; see also Table 1 in chapter 4). This stable TAT-SS-FlincG complex 
translocated randomly and distributed uniformly into all cell types found in small 
resistance vessels, including VSM cells (Figures 2 A, B). Upon intracellular entry, the 
reducing environment cleaves the TAT peptide and releases α-FlincG. To verify 
cytosolic localization of α-FlincG, we applied 8-Br-cGMP (50 µM) to FlincG-labeled, 
cerebral arteries (Figure 2 C).  
Recent studies in cultured VSM cells utilizing FlincG indicators revealed distinct 
spatio-temporal [cGMP]i kinetics depending on NO or ANP stimuli (Chapter 4, Figures 4 
and 5). Interestingly, similar temporal cGMP dynamics were detected in intact cerebral 
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arteries utilizing α-FlincG. Application of NO induced transient cGMP responses (lag 
time = 25 sec) with a maximum 1.3 fold increase in fluorescence intensity (Figure 3 A). 
The spatial distribution of [cGMP]i in response to NO in cerebral arteries could not be 
determined due to the slow frame rate of the confocal imaging system utilized in these 
experiments. In contrast to NO-evoked, transient cGMP kinetics, application of ANP 
(100 nM) induced sustained cGMP synthesis (lag time = 40 sec) with maximum 1.3 fold 
increase in fluorescence intensity (Figure 3 B). The spatial distribution of ANP-evoked 
[cGMP]i could not be resolved because of low-resolution epi-fluorescence imaging 
techniques. The overall low increase in intensity for α-FlincG is consistent with previous 
observations showing that different FlincG indicators (α- and β- FlincGs) generate small 
changes in the maximal fold intensity increase in cells due to interactions with 
endogenous proteins (Chapter 4: Figure 1 D; Tables 1 and 2). 
Although this novel, non-genetic delivery method for FlincG biosensors holds the 
potential to advance our understanding of the spatio-temporal dynamics of [cGMP]i in 
intact arteries, several complications still remain: relatively long incubation times (12-
15h) of the arteries are required to successfully deliver TAT-FlincG into VSM cells. This 
may result in precipitation of TAT-FlincG protein, as well as downregulation of key 
enzymes of the cGMP signaling cascade over time in arteries (Boerth et al., 1997; 
Browner et al., 2004). Furthermore, FlincG-loading efficiency is only modest (10-20%) 
and transient, since intracellular FlincG is degraded over time by proteases. Thus, future 
studies on [cGMP]i dynamics in intact tissue may greatly benefit from the development 
of FlincG transgenic mice. This transgenic approach is advantageous over current 
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methods, because [cGMP]i dynamics can be studied directly in freshly isolated arteries. 
Furthermore, tissue-specific expression of FlincG may reveal distinct cGMP patterns in 
various cell types such as vascular smooth muscle, cardiac myocytes or endothelial cells. 
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Methods 
Protein expression and purification 
To express α-FlincG, E.Coli BLR were transformed with α-FlincG-containing pRSET-A 
vectors and were cultured at 25°C for 12h after protein induction with 0.4 mM isopropyl-
β-D-thiogalactoside (IPTG). After centrifugation, α-FlincG was purified using cyclic 
nucleotide affinity chromatography as described previously (Feil et al., 1993). 
 
Cross-linking of α-FlincG with TAT and in vitro characterization 
To cross-label α-FlincG with TAT, purified protein (0.5 mg/ml) was mixed with a 50-
fold molar excess of Npys-TAT under nitrogen atmosphere. 200 nM recombinant TAT-
α-FlincG was combined with increasing concentrations of cGMP (0-10 µM) or cAMP (0-
100 µM) to generate cNMP dose response curves. Excitation spectra (detected at 510 nm) 
and emission spectra (excited at 410 or 480 nm) were taken using a fluorescence 
spectrophotometer F4500 (Hitachi, Tokyo, Japan).  
 
TAT-α-FlincG in intact cerebral arteries 
TAT-α-FlincG (50 µl) was then added to a canulated, pressurized, freshly isolated 
anterior, cerebral artery (~80-130um diameter) and incubated 12-15h at 37°C. Imaging 
for NO application was performed using the Noran OZ (Middleton, WI) laser scanning 
confocal system (10 second acquisitions; 60 x magnification). Epi-fluorescence imaging 
was performed to follow 8-Br-cGMP and ANP-evoked cGMP responses (10 sec 
acquisitions; 40 x magnification). 
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Figure legends: 
Figure 1: (A) Non-genetic delivery of TAT-FlincG into intact tissue. Surface accessible 
Cys residues of FlincG were labeled with an NPys-activated form of TAT. Following 
translocation into VSM cells within intact arteries, the carrier is cleaved and the biosensor 
is liberated. (B) cGMP and cAMP selectivity of recombinant TAT-α-FlincG. 
 
Figure 2: Rat cerebral arteries incubated with (A) TAT-α-FlincG and nuclear stain or (B) 
without any treatment. Confocal images were taken at 60 x magnification (see Methods). 
(C) Application of 50 µM 8-Br-cGMP. 
 
Figure 3: cGMP signaling in intact cerebral arteries upon application of (A) 5 µM DEA-
NO and (B) 100 nM ANP. 
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CONCLUSIONS AND FUTURE DIRECTIONS 
In this dissertation, we investigated in detail the mechanism of PKG activation 
using site-specific mutagenesis, electrospray ionization mass spectrometry, kinase 
activity assays, cGMP binding and dissociation studies (chapter two) as well as 
crystallography (chapter three). Based on the specific cGMP binding characteristics of 
PKG, we developed a new generation of cGMP biosensors to examine the spatial 
distribution of [cGMP]i in response to NO and ANP in VSM cells (chapter four) and in 
intact tissue (chapter five). 
In chapter two, we mutated several conserved aminoacids in the cGMP binding 
pockets of PKG regulatory domain to investigate the molecular mechanism of PKG 
activation. Based on site A and site B knock-out mutants (G167E, E168G, G291E, 
E292G), we suggest an overall concerted mechanism of activation for PKG I α that is 
significantly different form the sequential mechanism of PKA activation. Our results 
support coupling between both cGMP binding sites A and B, as well as coupling between 
cGMP binding site A and the catalytic domain. Furthermore, cGMP binding site B seems 
to play a pivotal role in modulating responsiveness of PKG to a broader range of 
[cGMP]i. In addition, the structural order of high and low affinity binding sites for PKG I 
α have been determined as sites A and B, respectively. We further investigated the roles 
of aminoacids arginine 177 and arginine 301, that are highly conserved among protein 
kinases, and that coordinate the phosphate backbone of cAMP in PKA (Bubis et al., 
1988; Zawadzki and Taylor, 2004). In contrast, our studies have shown that these highly 
conserved arginines are not essential for stabilizing cGMP in PKG. That raises the 
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question, what the functional role of the conserved arginine in the cGMP binding pocket 
is. It could still be involved in coordinating cGMP, but it might also be the discriminating 
factor for distinguishing between cGMP and cAMP binding. In addition to cGMP, 
binding and activation assays should be performed for cAMP to test the hypothesis that 
the conserved arginine plays a role in cGMP selectivity. PKA-selective inhibitors such as 
Rp-cAMPs have been shown to bind to the cAMP binding pocket in a certain steric 
conformation (Dostmann and Taylor, 1991). Therefore, the effect of PKG-selective 
inhibitors (Rp-cGMPs) on the arginine mutants should be examined. In particular, the 
crystal structure of PKG, or the regulatory domain, would be of great benefit to decipher 
molecular interactions between cGMP and the cGMP binding pockets and to unravel the 
molecular details essential for PKG activation. 
In general, crystallization studies require large quantities of protein, in order to 
screen as many conditions as possible for successful crystallization. PKG wildtype can 
only be expressed in a soluble form in (SF9-) insect cells (Feil et al., 1993), thereby 
demanding long expression times (>72 hours) and generally resulting in protein yields (< 
5mg/l) too low for crystallization. In chapter three, we developed successfully a bacterial 
expression and purification protocol for deletion fragments of the regulatory domain of 
PKG, resulting in protein quantities sufficient for crystallization (> 5 mg/ 50 ml). We 
attempted to crystallize these deletion fragments of the regulatory cGMP binding domain, 
as well as full-length, wildtype PKG utilizing Hampton Screens #1 and #2, and were able 
to obtain crystals and crystal-like structures (Figures 3 and 5, chapter 3). These 
preliminary crystallization conditions need to be refined in future studies by varying pH, 
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incubation temperature, salt- and precipitant concentrations. Fine-tuning these conditions 
and utilizing macro- or micro- seeding may result in enlarged PKG crystals that qualify 
for high diffraction and ultimately reveal a structural model for PKG. Although crystal 
structures will provide invaluable insights into PKG structure and function, they are static 
and limited in their use to study the dynamics of PKG in a physiologically-relevant 
environment. 
 To meet this challenge, we developed a new generation of cGMP biosensors 
(FlincG) to monitor cGMP signaling in living cells and in intact tissue (Chapters 4 and 5). 
FlincG excels in monitoring [cGMP]i in response to physiological (low-nanomolar) NO 
concentrations and is suitable for high-resolution, real-time confocal microscopy. FlincG 
revealed the differential role of PDE-5 in the modulation of global cGMP in response to 
NO donors, and the spatial spread of cGMP away from the cell membrane in response to 
ANP.  FlincG holds the promise of unraveling the complex interplay between cGMP and 
calcium signaling near the cell membrane and should ultimately be suitable for 
development of tissue-specific generation of transgenic mice with endogenous cGMP 
indicators, as has been done recently for calcium sensing with GCaMP (Ji et al., 2004; 
Tallini et al., 2006). One of the most important criteria for developing a transgenic mouse 
is the maximal signal-to-noise ratio of the biosensor. For GCaMP, the recombinant 
protein displayed 4-fold maximal fluorescence intensity change upon stimulation (Nakai 
et al., 2001), but in the transgenic GCaMP-mouse, the change in fluorescence intensity 
was decreased to approximately 1.6 fold (Ji et al., 2004; Tallini et al., 2006). GCaMP is 
composed of cpEGFP sandwiched between calmodulin and M13. The reduction in 
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fluorescence intensity in transgenic mice is most likely due to interactions of calmodulin 
and M13 with endogenous proteins. Our FlincG indicators, however, were specifically 
designed to prevent interactions with endogenous PKG, by deleting the N-terminal 
dimerization domain. Therefore, the overall maximal 1.75 fold increase in fluorescence 
intensity should not vary between recombinant δ-FlincG and the biosensor in transgenic 
mice. Furthermore, overall signal strength of the biosensor should be verified, by 
comparing the basal fluorescence of EGFP-transfected cells with δ-FlincG transfected 
cells. This is important, since a very ‘dim’ indicator could not be distinguished from auto-
fluorescent cells in a transgenic mouse. 
To study in greater detail the role of compartmentalized cGMP signaling, FlincG 
should be fused to the GC-A receptor to co-localize the biosensor to the cell membrane. 
Similarly, FlincG can be tethered to phosphodiesterases, G-protein kinase anchoring 
proteins, or to cyclic nucleotide gated ion channels to force the biosensor into close 
proximity to target molecules and to study cGMP dynamics together with calcium in 
spatially distinct compartments in cells. Currently, FlincG offers the exciting possibility 
to study calcium and cGMP dynamics simultaneously, by utilizing Fura- or Rhodamine- 
calcium dyes. To expand the variety of imaging options, cpEGFP in FlincG may be 
replaced by other circular permutated fluorophores (e.g. tangerine). The concept of this 
new generation of cGMP indicators may also set the stage for the development of non-
FRET based cAMP biosensors. This approach holds the exciting potential to investigate 
not only the cross-talk between cGMP and calcium, but also between cGMP and cAMP, 
by utilizing modified FlincG and FRET-based cAMP indicators simultaneously.  
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In the future, FlincG can be used as a tool not only to address physiologically 
relevant questions, but also to study the structure and function of PKG. FlincG biosensors 
are composed of the regulatory domain of PKG fused to the N-terminus of cpEGFP. 
Since FlincG biosensors can be expressed in bacteria and purified to reasonable yield (> 7 
mg/l), they are prime candidates for crystallization studies. Screening for FlincG-crystals 
should be facilitated by the fact that the presence of green fluorescent protein (GFP) 
'stains' the crystals green. Furthermore, the structure-solving process of FlincG should be 
fairly straight forward, since the crystal structure of GFP (Ormo et al., 1996) can be 
utilized for molecular replacement. The structural characterization would allow us to gain 
insight into the regulatory domain of PKG as well as into the folding properties that 
define cGMP biosensors. In addition, the overall change in fluorescence intensity of 
FlincG can be used as read-out system to screen for novel PKG inhibitors and activators. 
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